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TARGETING ZINC FINGER 304 (ZNF304) BY DUAL ASSEMBLY 
NANOPARTICLES (DANP) IN OVARIAN CANCER 
 
Burcu Aslan, M.S. 
Supervisory Professor: Gabriel Lopez-Berestein, M.D. 
Abstract 
 
Ovarian cancer (OC) is a highly metastatic disease, but no effective strategies to 
this process currently are known. Here, an integrated computational analysis of 
The Cancer Genome Atlas ovarian cancer dataset coupled with experimental 
validation identified a novel zinc finger transcriptional factor 304 (ZNF304) as one 
of the key factors for ovarian cancer metastasis. High tumoral ZNF304 
expression was associated with poor overall survival in ovarian cancer patients. 
Through reverse phase protein array analysis, we demonstrated that ZNF304 
promotes multiple proto-oncogenic pathways important for cell survival, 
migration, and invasion. ZNF304 transcriptionally regulates β1 integrin, which 
subsequently regulates Src/focal adhesion kinase and paxillin and prevents 
anoikis. Targeting ZNF304 using small interfering RNA (siRNA) reduces cell 
survival, anoikis and migration in vitro. A novel dual assembly nanoparticle 
system (DANP) was designed for in vivo delivery and sustained gene silencing. 
DANP-ZNF304 siRNA led to sustained ZNF304 silencing for 14 days, increased 
anoikis, and reduced tumor growth in orthotopic murine models of ovarian 
cancer. Taken together, ZNF304 is a novel transcriptional regulator of β1 
integrin, promotes cancer cell survival, and protects against anoikis in ovarian 
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cancer; DANP is a safe and efficient delivery system that provides prolonged 
gene silencing following systemic administration. 
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CHAPTER I: Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Parts of this section were adapted with permission in part from Aslan, B et al., Nanotechnology in 
Cancer Therapy from Journal of Drug Targeting, 2013; and from Aslan, B et al., Chitosan 
Nanoparticles, Encyclopedia of Nanotechnology, 2012) 
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Nanotechnology In Cancer  
 
Cancer is one of the leading causes of morbidity and mortality worldwide and it is 
expected to be the major cause of death in the coming decades (Bray et al., 2012). 
Despite the advances and extensive research on novel approaches, current treatments 
are still limited to surgery, radiotherapy, chemotherapy, and immunotherapy. Treatment 
failure is related to either drug resistance, pharmacological or toxicity issues in most 
instances. In contrary, utilization of nanocarriers leads to increased therapeutic index 
and tumor tissue concentrations of the drugs and can enhance the efficacy of currently 
used regimens by providing superior pharmacokinetic features, extended blood 
circulation time, and elevated cellular uptake that are major factors for an improved 
therapeutic window and subsequent clinical success. Advances in nanotechnology are 
also expected to provide foundation for development of novel therapeutics and wide 
applications of diagnostic methods in cancer. 
 
Key factors in selecting biomaterials are biocompatibility, biodegradability, safety and 
ease of assembly in the structures with the desired characteristics. Taken together, 
biomaterials and nanotechnology offer a unique opportunity to improve survival in 
cancer patients. In this part of the chapter, I will focus on strategies of nanoparticle 
design and highlight the latest developments in cancer nanomedicine. 
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Nanoparticles 
 
The history of nanoparticles starts in 1950s with a polymer-drug conjugate that was 
designed by Jatzkewitz (Jatzkewitz, 1954), followed by Bangham who discovered the 
liposomes in mid-1960s (Bangham and Horne, 1964), (Bangham et al., 1965). In 1972, 
Scheffel and colleagues first reported albumin based nanoparticles (Scheffel et al., 
1972), which formed the basis of albumin-bound paclitaxel (Abraxane). Abraxane was 
approved in 2005 by US Food and Drug Administration (FDA) for the treatment of 
breast cancer (Gradishar et al., 2005) and recently approved for the treatment of lung 
cancer (Casaluce et al., 2012). Abelcet, amphotericin B lipid complex, was approved by 
FDA (Chonn and Cullis, 1995) for the treatment of invasive fungal infections and it is 
widely used to treat systemic fungal disease, which is a source of major morbidity in 
cancer patients (Herbrecht, 1996).  
 
In the 1980s, Maeda and colleagues observed the enhanced accumulation of 
nanoparticles in the tumor site due to the altered structure of tumor vasculature 
(Matsumura and Maeda, 1986). Blood vessels in tumors are different compared to 
normal blood vessels due to abnormal and leaky architecture. Impaired regulation in 
blood vessels leads to ‘enhanced permeability and retention (EPR) effect’ (Maeda et al., 
2006). The reduced lymphatic drainage, increased size of fenestrations and gaps 
between endothelial cells, varies from 200 to 1200 nm, in contrast to normal 
endothelium with pores with 10 to 50 nm contributes to EPR effect. This effect has 
become a hallmark of the solid tumor vasculature leading to increased nanoparticle 
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accumulation in the tumor site due to ‘passive targeting’. Hereby drug carriers exhibit 
enhanced therapeutic efficacy in tumors, in addition to reduced side effects and toxicity.  
Despite the advantages of passive targeting approaches, several limitations exist that 
still needs to be eliminated in the future. Certain tumors are difficult to deliver due to 
lack of EPR effect, hence the permeability in blood vessels may not be identical 
throughout the same tumor (Yuan et al., 1995). To overcome these limitations, 
nanoparticles are designed to bind to specific targets (active targeting) through the 
ligands that recognize particular receptors in target cells.  
Active Targeting 
 
Various receptors on the tumor cell surface have been studied as potential sites to 
achieve selective delivery. Nanoparticle surface can be modified by a variety of 
conjugation chemistries to attach specific receptor ligands (Torchilin, 2005). 
Nanoparticles recognize and bind to their targets with subsequent uptake through 
receptor mediated endocytosis. Once internalized, the drug or payload is released in the 
cytoplasm or nucleus. Such receptor ligands may be peptides, vitamins, antibodies, 
carbohydrates and other chemical structures. For instance, the overexpression of 
transferrin and folate in certain tumors have been exploited to deliver nanoparticles 
conjugated with these receptor’s ligands (Yang et al., 2010), (Fernandes et al., 2008). 
Another example is the ανβ3 integrin, which is overexpressed in a wide range of tumors 
and angiogenic tumor-associated endothelium, and is largely absent in normal tissues. 
Han and colleagues have recently reported that the administration of chitosan 
nanoparticles conjugated with cyclic Arg-Gly-Asp (RGD) led to increased tumor delivery 
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and enhanced anti-tumor activity in ovarian cancer models (Han et al., 2010) (Fig.1). A 
variety of targeting agents such as monoclonal antibodies (mAbs) and nucleic acids 
(aptamers) are also used to enhance tumoral uptake of nanoparticles. Using mAbs for 
targeting in cancer therapy was first described by Milstein in 1981 (Warenius et al., 
1981). Since then, antibody-based targeting has made a significant progression as a 
feasible strategy in cancer therapy. Clinically approved and widely used mAbs include 
rituximab (Rituxan) for the treatment of non-Hodgkin’s lymphoma (James and Dubs, 
1997), trastuzumab (Herceptin) for breast cancer treatment (Albanell and Baselga, 
1999), bevacizumab as an angiogenesis inhibitor in colorectal cancer (Ferrara, 2005). 
Since 1997, 12 mAb-based therapy have been approved and a large number of 
antibody-based strategy is in progress for preclinical or clinical trials (Scott et al., 2012). 
Conjugation of an antibody directly to a therapeutic agent has been also explored. 
Mylotarg was the first approved formulation with this regard in clinic. Calicheamicin is a 
chemotherapeutic agent and it was conjugated with the CD33 antibody (Peer et al., 
2007). Zevalin and Bexxar are radio-immunoconjugates formulated by using CD20 
antibody and approved for the treatment of non-Hodgkin’s lymphoma (Grillo-López, 
2002), (Blagosklonny, 2004). 
 
Recently, nucleic acid aptamers have gained immediate attention after the in vitro 
selection of functional nucleic acids (termed SELEX) that was discovered in 1990 
(Ellington and Szostak, 1990, Tuerk and Gold, 1990). Aptamers are single stranded 
oligonucleotides that can modulate molecular targets with high specificity and affinity 
through their three-dimensional structures. Aptamers exhibit significant advantages 
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such as the technical possibility in selection and chemical modification, specificity to 
target any given molecule, its substantial bio-activity in vivo, the low production costs, 
the simplicity in synthesis and storage for the marketing (Scaggiante et al., 2013). There 
are currently several aptamers that are in clinical trials (Scott et al., 2012). For instance, 
Pegaptanib was approved by FDA and used as a VEGF-specific aptamer that binds to 
VEGF and blocks the interaction with its receptor (VEGFR) thereby inhibiting its activity 
(Gragoudas et al., 2004). Moreover, aptamers seem alluring to modify the surface of 
nanoparticles for the design of targeted drug delivery systems. 
 
Drug Delivery Systems  
Liposomes  
Liposomes are self-assembling nanoparticles formed by dispersion of phospholipids 
with hydrophilic heads and hydrophobic anionic/cationic long chain tails, creating closed 
membrane structures. Hydrophilic agents such as drugs and siRNA or hydrophobic 
drugs can be incorporated into the inner compartments and, into the hydrophobic 
membranes respectively. Currently, several liposomal anticancer drugs are used 
successfully as carriers in the clinic or studied in advanced stages of clinical trials. For 
instance, doxorubicin loaded liposomes were modified with polyethylene glycol (PEG) 
that alters the plasma pharmacokinetics and tissue distribution of doxorubicin and this 
PEGylated liposomal doxorubicin (Doxil) carriers, were approved by FDA for the 
treatment of Kaposi’s sarcoma (Patel, 1996). Along with Doxil, approved liposomal 
formulations include non-pegylated liposomal doxorubicin (Myocet by Elan), liposomal 
daunorubicin (DaunoXome by Gilead), liposomal amphotericin B (abelcet), liposomal 
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cytarabine (DepoCyte by SkyePharma/Enzon/Mundipharma) and liposomal cisplatin 
(Lipoplatin by Regulon) (Huwyler et al., 2008). On the other hand, antisense 
oligonucleotides are also attractive to be used in liposomal formulations for cancer 
therapy (Tari et al., 1995). Antisense oligonucleotides can selectively inhibit disease-
causing genes and thereby inhibiting the production of disease associated-proteins. For 
instance, liposomal formulation of bcl-2 oligos was demonstrated to inhibit bcl-2 protein 
production thereby leading to a growth inhibition in follicular lymphoma cell lines (Tormo 
et al., 1998). Furthermore, liposomal bcl-2 antisense oligos were studied to evaluate the 
in vivo behavior in rodents. The liposomes were widely distributed and no significant 
toxicity was observed over 6-week treatment of intravenously administered liposomal 
Bcl-2 oligos (Gutiérrez-Puente et al., 1999). Another example is raf antisense 
oligonucleotide that inhibits c-raf that leads to enhanced sensitivity to radiation and 
chemotherapy. LErafAON is the liposomal formulation of raf oligonucleotide that 
showed success for advanced solid tumors in its Phase I study (McGinnis et al., 2012). 
 
Polymeric micelles 
Polymeric micelles are formed from self-assembly of amphiphilic-block copolymers 
ranging between 10-100 nm in size. They are composed of a hydrophobic core and a 
hydrophilic corona. Micelles can improve the bioavailability of hydrophobic drugs, confer 
protection and inactivation of the drugs under the effect of biological surroundings 
(Torchilin, 2001). Polymeric micelle formulations are used for both passive and active 
targeting in anticancer therapy. For example, Genexol-PM is currently under 
investigation as a paclitaxel loaded polymeric micelle formulation for the treatment of 
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breast, lung, and pancreatic cancer. Pluronic and NK911 are doxorubicin loaded micelle 
formulations that are also currently studied in Phase I (Sultana et al., 2013). NC-6004 is 
carboplatin loaded formulation that is also studied in early clinical trials for the treatment 
of solid tumors (Wilson et al., 2008). Furthermore, there are polymeric micelle 
formulations that are designed for active targeting and modified with different ligands 
such as folate (binds to folate receptor) and mAb C225 (binds to EGF receptor). In a 
nude mice xenograft model, doxorubicin loaded PLGA-b-PEG polymeric micelle 
formulation has been shown to increase tumoral uptake and significant tumor 
regression (Yoo and Park, 2004). 
Dendrimers 
Dendrimers are hyperbranched nanoparticles composed of a core, branching units and 
functionalized terminal groups. The major advantage of dendrimers is that multiple 
anticancer agents can be incorporated in the central core or conjugated to functional 
end groups (Lee et al., 2005). In addition, depolymerization of dendrimers can be 
controlled to modify release profiles of the payload (Wong et al., 2012). For example, 
polyamidoamine (PAMAM) dendrimers can be tailored to enhance their biocompatibility 
and release properties through PEGylation, acetylation, and modified with anionic, 
neutral ligand molecules (Cai et al., 2013). As an example, doxorubicin was conjugated 
to PEGylated PAMAM dendrimers by acid-sensitive linkages in order to trigger the 
release of doxorubicin in acidic conditions (Zhu et al., 2010). Evaluations of pH-
dependent payload release, cytotoxicity, cellular uptake and intracellular localization 
were performed using SKOV-3 ovarian cancer cell line. In addition, dendrimers with 
highest PEGylation degree showed the maximum- accumulation in SKOV3 tumor 
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xenografts in mice. On the other hand, polylysine dendrimers conjugated with a ligand 
for α5β1 also known as fibronectin receptor was designed for tumor targeting. Activated 
α5β1 is highly expressed in breast cancer cells compared to non-transformed cells and 
it plays a vital role in invasion and metastasis pathways in cancer. PHSCN peptide is a 
ligand that interacts with a specific region of the α5 subunit of integrin thereby blocking 
its activity. Polylysine dendrimers can be modified with this ligand for tumor targeting 
and the treatment with this carrier led to a significant reduction in the number of invasive 
human breast cancer cells (Yao et al., 2011). Furthermore, when tumor bearing mice 
were treated with polylysine dendrimers modified with integrin ligand, lung colony 
formation was obviously inhibited. In conclusion, despite the fact that dendrimers are 
extensively used for the design and development of therapeutics, further research is 
needed to improve its immunogenicity to assure the safety of long-term administration in 
clinic. 
Polymeric nanoparticles 
Polymer based delivery systems show great promise for biomedical applications due to 
their high biocompatibility and flexibility in which their structures can be modified to 
engineer multifunctional nanoparticles with desired shape, size, internal and external 
morphology as well as surface modifications. During the preparation stage of 
nanoparticles, polymers can be utilized through isolation from their natural sources such 
as chitosan that is produced from chitin or they can be synthesized in the desired 
structure such as poly-lactic-co-glycolic acid (PLGA). PLGA, arginine, chitosan, human 
serum albumin, alginate, and hyaluronic acid have been widely used in preclinical 
studies for drug delivery. Polymer based nanoparticles shows great promise in 
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preclinical studies. For example, chitosan nanoparticles are one of the most popular 
polymeric delivery system that is widely used in particular gene delivery. Chitosan 
nanoparticles serve as an attractive candidate for small interfering RNA (siRNA) 
delivery due its positive charge. Electrostatic interactions between negatively charged 
siRNA and positively charged chitosan create a safe carrier for siRNA in the blood 
circulation. Kim and coworkers analyzed the therapeutic effects of src and fgr inhibition 
using siRNA incorporated chitosan nanoparticles in orthotopic models of ovarian 
cancer. Dual silencing of src and fgr with chitosan nanoparticles in vivo, led to a 
significant reduction in tumor growth (Kim et al., 2011). 
 
For clinical studies, albumin bound paclitaxel (abraxane) is the first polymeric 
formulation that is approved by FDA for the treatment of metastatic breast cancer 
(Gradishar et al., 2005) and it is recently approved for the treatment of lung cancer. 
Abraxane exploited the ability of albumin to bind to 60-kDa glycoprotein (gp60) receptor 
(albondin) (Miele et al., 2009). After this receptor-ligand interaction, albumin-gp60 
complex triggers caveolin-1 mediated uptake of protein bound plasma molecules. On 
the other hand, albumin also binds to osteonectin (secreted protein acid rich in cysteine 
[SPARC] due to a sequence homology with gp60. SPARC is highly expressed in 
particular neoplasms (breast, prostate, and lung cancer) and contributes to intratumor 
accumulation of all albumin-bound drugs (Hawkins et al., 2008). In addition, Livatag 
(Doxorubicin Transdug) is a poly (isohexyl cyanoacrylate) nanoparticle formulation 
loaded with doxorubicin and approved for the treatment of multidrug-resistant protein-
overexpressing hepatocellular carcinoma (Sultana et al., 2013).   
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Characteristics of Nanoparticles  
 
Physical and chemical characteristics of nanoparticles including size, charge, shape, 
and surface properties individually play major roles for in vivo biodistribution and cellular 
internalization of these drug carriers. In this section, we will focus on the major 
parameters that determine the lifetime and delivery of the nanoparticles. 
Size  
Particle size is one of the crucial primary factors in determining the circulation time of 
the nanoparticles. After systemic administration, nanoparticles accumulate in spleen 
due to mechanical filtration and removed by reticulo-endothelial system (RES). For 
example, as the main constituent of RES, Kupffer cells play a major role for the removal 
of the particles accumulated in the liver (Moghimi et al., 2001). Currently, 100-200 nm is 
accepted as optimal size for drug delivery systems since nanocarriers take the 
advantage of EPR effect in tumors and avoid filtration in the spleen whereas they are 
large enough to avoid the uptake in the liver (Petros and DeSimone, 2010). Particles 
with a smaller diameter than 5nm are rapidly cleared from blood circulation through 
renal clearance or extravasation (Wong et al., 2008), (Alexis et al., 2008), (Choi et al., 
2007). However, particles with a size up to 15 µm; accumulate in liver, spleen and bone 
marrow (Petros and DeSimone, 2010).  
 
In addition, particle size has a significant impact on cellular internalization through 
phagocytosis, macropinocytosis, caveolar-mediated endocytosis, clathrin-mediated 
endocytosis. As mentioned above, size range has high influence on biodistribution and 
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cellular internalization. In addition, recent studies show that the geometry of the 
particles is as important as size range in terms of cellular internalization and distribution 
(Geng et al., 2007), (Decuzzi et al., 2010). In addition, Gratton and coworkers studied 
the correlation between shape and size on the internalization frequency in HeLa cells 
and interestingly, the particles with different shapes but similar volumes were 
internalized at extremely assorted rates (Gratton et al., 2008). In a distinct study, Godin 
and coworkers demonstrated that the accumulation of discoidal particles in breast 
tumors were five times higher than spherical particles despite their similar diameters 
(Godin et al., 2012). As a result, accumulating evidence shows that although size is a 
major parameter in the design of nanocarriers for decades, the shape as well, has a 
high impact along with the size. 
Shape 
Degradation properties of nanoparticles and subsequent payload release have been 
shown to be dependent on particle shape (Bawa et al., 1985). The importance of 
surface area and diameter were also demonstrated to be critical for cellular uptake of 
the nanoparticles (Panyam et al., 2003), (Dunne et al., 2000). Hemi-spherical particles 
were generated as sustained release devices in order to achieve zero-order. Spherical 
particles, however, can provide different degradation profiles as their shapes are 
susceptible upon degradation (Champion et al., 2007). Additionally, deformability of 
spherical nanoparticles is also playing a key role to avoid spleen filtration since spleen 
exhibit asymmetric filtering units (Moghimi et al., 2001). Therefore, nanoparticles which 
are especially larger than 200 nm should be either deformable enough to bypass the 
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filtration in spleen or flexible as erythrocytes that can avoid filtration even with 10 µm 
diameter. 
In an elegant study, Decuzzi and co-workers studied the effect of size and shape of 
nanoparticles on biodistribution and tumor accumulation after intravenous injection. 
Spherical silica particles were generated in different sizes ranging from 700 nm to 3µm 
also in different shapes such as quasi-hemispherical, discoidal, and cylindrical silicon 
based particles. After a single, intravenous particle injection to tumor bearing mice, 
tumors and the major organs including liver, spleen, heart, lungs, kidneys, and brain 
were analyzed for silicon content and histological evaluation. This study elucidated the 
importance of shape properties of nanoparticles in addition to size distribution, 
indicating that geometry of the nanoparticles contributes to opsonization, in vivo 
biodistribution, the strength of adhesion and internalization rate in the cells (Decuzzi et 
al., 2009). 
Surface characteristics 
Surface properties play a key role on the period of nanoparticles in blood circulation 
subsequent systemic administration. After administration, nanoparticles may be 
associated with proteins, which are known as ‘opsonins’, such as immunoglobulins, and 
complement proteins that contribute to recognition of nanoparticles by macrophages. 
Therefore, opsonization is the key factor that determines the fate of nanoparticles to an 
extent in blood circulation.  Modifying the surface of nanoparticles can be used as a 
strategy to enhance or reduce their circulation time in blood and tissues. For instance, 
negatively charged nanoparticles result in rapid RES clearance from circulation (Zahr et 
al., 2006). Cationic surfaces may induce cell membrane permeability and enhance 
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cellular uptake (Chen et al., 2009) however, cationic nanoparticles prepared from 
polycationic polymers such as polyethyleneimine and diethylaminoethyl-dextran can 
induce disruption in the cell, through formation of holes, membrane thinning and 
membrane erosion in lipid bilayers (Leroueil et al., 2008).  On the other hand, the use of 
neutrally charged particles as well as particles coated with polyethylene glycol (PEG) 
lead to a major reduction of particle uptake by the RES (Torchilin and Trubetskoy, 1995, 
Otsuka et al., 2003). 
 
The surface modification of PEGylated liposomes with rat serum albumin (RAS), 
compared with non-modified PEGylated liposomes, showed prolonged blood circulation 
in rats. To further analyze, total serum protein amounts were determined quantitatively 
in the absence and presence of RAS coating. As a result, RAS-modified liposomes 
significantly reduced the total amount of serum proteins that can induce opsonization in 
serum (Furumoto et al., 2007). In addition, doxorubicin-loaded and albumin-modified 
liposomes demonstrated enhanced pharmacokinetics and tissue distribution of 
doxorubicin (Yokoe et al., 2008). Tumor accumulation and therapeutic index of albumin-
modified PEGylated liposomal doxorubicin was significantly higher than non-modified 
PEGylated liposomal doxorubicin indicating that surface modification of nanoparticles 
with albumin, enhances their safety and effectiveness. 
 
In addition, nanoparticle surface can be modified with ligands that recognize and bind to 
specific receptors. Also, monoclonal antibodies can be conjugated onto nanoparticle 
surface to provide specificity. For instance, nanoparticles modified with HER2 specific 
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antibody, delivers the drug, particularly HER2 expressing cells (Kirpotin et al., 2006). 
Torchilin’s group has also designed different approaches for active targeted delivery to 
the tumor with liposomes and micellar delivery systems. They have developed 
monoclonal antibody 2C5-modified doxorubicin loaded liposomes to enhance the 
therapeutic activity of the payload in brain tumor xenografts (Gupta and Torchilin, 2007) 
These studies demonstrate that surface characteristics are fundamentally important for 
nanoparticles to avoid  their rapid clearance from the blood circulation before reaching 
the tumor site, and to provide active targeting through surface modifications with 
antibodies or ligands. 
Release characteristics 
The release properties of nanoparticles determine the efficiency of the treatment at 
target sites. Conventional drugs used in clinic have a narrow therapeutic window due to 
rapid increase and decrease of plasma drug levels after systemic administration, 
resulting in bordering doses with subsequent side effects (Figure 1A). However, drug 
delivery systems aims at delivering the desired concentration of the drug within the 
therapeutic range at target site, culminating minimized side effects and discomfort in 
patients (Figure 1B). 
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Figure 1. Drug levels in plasma after systemic administration  
Graphs representing the drug levels in plasma over time after administration of (A) 
conventional drugs and (B) drug delivery for sustained release. 
 
 
Constant plasma drug levels over a long period of time can be attained through zero-
order release kinetics that can be achieved by using osmotic pressure, mechanical 
pumping, and electrokinetic transportation (Sakamoto et al., 2010). Besides, 
biocompatible polymeric nanoparticles are also used to prolong the period of drug 
release due to their long biodegration time in a range from days to months. Particularly, 
molecular weight is a major parameter in biodegradation rate of polymers. For instance, 
poly lactide-co-glycolide (PLGA) and poly lactic acid (PLA) were both used in order to 
study the sustained release of docetaxel after intravenous administration (Musumeci et 
al., 2006). Release rate of the drug has been shown to highly associate with molecular 
weight of the polymers. Furthermore, polymer with high molecular weight led to slower 
degradation of the material, compared to the polymer with low molecular weight, 
resulting in sustained release of the payload. 
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Multistage delivery system is an additional alternative approach providing sustained 
release of the payload where mesoporous silicon particles (MSP) offer unique 
opportunities for drug delivery (Tanaka et al., 2010). MSPs size, charge, shape, porosity 
are among the characteristics that can be tailored for particular applications and 
objectives of its use. We have used MSPs loaded with nanoliposomes carrying small 
interfering RNA (siRNA) that leads to target mRNA degradation. In this study, 
degradation of silicon particles allowed for the long-term release of siRNA to the target 
site (Shen et al., 2013a, Tanaka et al., 2010).  
 
Another strategy to control the release of the payload can be using the environment of 
target site as a driving mechanism. Environment responsive nanocarriers offer a unique 
strategy, in particular, when the stimulus is specific to the disease pathology (Ganta et 
al., 2008). The approach seems promising since the stimuli trigger the payload to 
diffuse out of the particles through a controlled drug release. The biological stimuli 
include pH, temperature, and redox microenvironment (Shenoy et al., 2005), 
(Kommareddy and Amiji, 2005). Recently, Chen and colleagues have designed dual 
responsive- doxorubicin loaded polymeric micelles that release the payload in response 
to temperature and pH (Chen et al., 2012). In this study, drug release was analyzed at 
different pH conditions such as physiological condition (pH 7.4), endosomal (pH 6.6 and 
6.0), lysosomal (pH 5.4), and different temperature conditions. Doxorubicin release rate 
was associated with increased temperature and decreased pH. Furthermore, they have 
demonstrated enhanced antitumor activity in tumor bearing mice that were generated by 
subcutaneously injected HeLa cells. On the other hand, external stimuli can be used to 
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trigger the release such as magnetic field, mild temperature increase or ultrasound 
(MacEwan et al., 2010). For instance, ultrasound triggers the degradation of polymers, 
slightly increases the temperature and cell membrane permeability, ultimately resulting 
in the release of the drug at target site (Mitragotri, 2005). Cisplatin release upon low 
frequency ultrasound has been demonstrated by Schroeder and colleagues (Schroeder 
et al., 2009). In this study, cisplatin-loaded liposomes were intraperitoneally 
administered into tumor bearing mice and the release of cisplatin was triggered by 
ultrasound at tumor site. Despite the tremendous progress in the design and 
development of nanoparticles, further preclinical studies are still required to conduct 
clinical trials for cancer therapy.  
 
Advances in nanomedicine offer new opportunities to improve the anticancer 
armamentarium. Targeted and nontargeted nanoparticles are currently in preclinical and 
clinical phases indicating the impact of delivery systems on the field. Further studies in 
nanomedicine will improve therapeutic window of drugs with immensely reduced side 
effects leading to improved patient outcomes. 
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Ovarian Cancer 
 
Ovarian cancer (OC) has the highest mortality rate among gynecologic malignancies. In 
the United States in 2014, over 21,000 women will be diagnosed with OC, and more 
than 14,000 women will die (Siegel et al., 2014). The poor survival rate in patients is 
due to the late-stage presentation of the disease. Despite the ongoing studies on 
screening strategies, only 20% of ovarian cancers can be diagnosed at stage 1, in 
which the disease is still limited to ovaries. When it metastasizes to the pelvic organs 
(stage 2), the abdomen (stage 3) or the peritoneal cavity (stage 4), the five-year median 
survival rate decreases down to 40 % (Vaughan et al., 2011).  
 
Ovarian cancers are notably heterogeneous at cellular level and different ovarian 
tumors arise from distinct cell types. The normal ovary contains three major cell types: 
germ cells, endocrine and interstitial cells, and epithelial cells. Tumors that arise from 
germ cells constitute 3-5% of ovarian cancers whereas sex-cord-stromal tumors 
account for 7% of all ovarian malignancies. However, approximately 90% of the 
malignant ovarian tumors originate from the surface epithelium and in general, cancer 
develops after age 40 (Romero and Bast Jr, 2012). Number of ovulatory cycles and a 
family history of ovarian, breast, uterine, or colon cancer are major risk factors for 
patients.  
 
OC can be classified into two major groups based on histological grade, molecular 
phenotype, and genotype; Type II and I. Type I cancers are often diagnosed in early 
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stages (I and II) and grow slowly whereas Type II cancers usually characterized by its 
late stage presentation (III-IV) and aggressive growth (Romero and Bast Jr, 2012).  
 
The histotypes of OC are: serous, endometrioid, mucinous and clear cell (Figure 2). 
These histotypes are associated with HOXA9, HOXA10, and HOXA11 genes that 
control the normal gynecological differentiation (Cheng et al., 2005). Tumor histotypes 
and grades are critical factors in order to determine the diagnosis and the prognosis 
(Soslow, 2008),(Silverberg, 2000). Numerous invasive mucinous ovarian cancers are 
metastases to the ovary, often from the gastrointestinal tract, including the colon, 
appendix or stomach. Endometrioid and clear cell ovarian cancers originate in 
endometriosis, which is linked to menstruation from the endometrium (Figure 2) 
(Vaughan et al., 2011).  
 
The most common histological subtype is high-grade serous OC (HGSOC), and the 
poor survival rate associated with this subtype is primarily due to the advanced stage of 
disease and widespread metastases, at the time of diagnosis. The rapid spread of 
HGSOC is based on its propensity to seed the peritoneal cavity, leading to ascites 
formation and metastases (Naora and Montell, 2005) (Kipps et al., 2013). Ascites 
formation occurs through the blockage of diaphragmatic lymphatics that restrains the 
outflow of the fluid from the peritoneal cavity, leading to the accumulation of ascites fluid 
abdominal swelling in advanced stages (Romero and Bast Jr, 2012). 
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Figure 2. Origin and histotypes of ovarian cancer 
This figure is used with permission and originally published by Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., 
Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. C.,Drapkin, R. & Etemadmoghadam, D in 2011 in Nature Cancer 
Reviews 
	  
 
Molecular alterations are also critical in the development and progression of OC. TP53 
is mostly mutated in high-grade tumors whereas BRAF and KRAS mutations are more 
frequent in low-grade serous tumors. Clear cell and endometrioid tumors commonly 
exhibit mutations in PI3K pathway (PTEN, PIK3CA) and RAS mutations are mostly 
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assessed in mucinous OC (Coleman et al., 2013). Inherited BRCA1 and BRCA2 
mutation mostly lead to Type II tumors (Sessa and Del Conte, 2010). 
 
In the treatment of ovarian cancer, surgery has a pivotal role for the extended survival of 
the patient. It is then followed by a combination of carboplatin- and taxane-based 
therapy. Although 70 % of patients respond to the initial therapy at this stage, drug 
resistant cells can remain dormant in the peritoneal cavity and lead to recurrent disease 
(Bast et al., 2009). 
 
Carboplatin is an alkylating agent that binds covalently to DNA; thereby creating 
adducts that form intrachain or interchain crosslinks. Paclitaxel increases microtubule 
stability through non-covalent interaction and prevents the mitotic spindle formation. 
Platinum-based cancer therapy was first introduced in late 1970s with cisplatin. Then it 
was replaced with carboplatin that has lower toxic effects in combination with other 
agents such as taxanes (Figure 3) (Vaughan et al., 2011). The combination therapy can 
improve survival rather than single agent treatment. For instance, combination of 
carboplatin with paclitaxel (Parmar et al., 2003, Gonzalez-Martin et al., 2005), 
gemcitabine (Pfisterer et al., 2006), or liposomal doxorubicin (Pujade-Lauraine et al., 
2010) leads to better survival than single carboplatin treatment (Bast and Markman, 
2010). 
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Figure 3. Evolution of chemotherapy for ovarian cancer 
This figure is used with permission and originally published by Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., 
Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. C.,Drapkin, R. & Etemadmoghadam, D in 2011 in Nature Cancer 
Reviews 
 
Overall, chemotherapy improves the survival of patients however the tumor relapse in 
most cases and long-term survival rate is relatively low. The primary reason of the 
treatment failure is the development of drug resistance. Thus, identification of new 
targets and a better understanding of the biology behind the tumor growth and survival 
are required. 
 
Given the heterogeneity of OC at molecular level, extensive characterization of cancer 
specimens is required in order to find out the altered genes and/or proteins that can be 
targeted in patients. DNA sequencing of relevant genes, high-resolution comparative 
genomic hybridization, single nucleotide polymorphism analysis, expression arrays, 
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reverse phase protein arrays can be carried out for further characterization of the 
tumors (Bast et al., 2009). In addition, The Cancer Genome Atlas (TCGA) database 
reveals the expression of relevant genes in a variety of tumor types and the correlation 
with survival in patients.  
 
RNAi-based screenings are carried out not only to find out new targets in ovarian 
cancer cells but also to knockdown the relevant genes in vitro and in vivo. RNAi based 
therapies offer a unique opportunity to knockdown specific genes and paves the way to 
personalized medicine in cancer therapy. In order to achieve sufficient delivery of RNAi, 
biological barriers have to be overcome. This emphasizes the crucial role of 
nanotechnology-based carriers in the development of novel strategies.  
Early-phase RNAi based therapy trials drew the attention to the feasibility of siRNA 
delivery into tumors and the selective knockdown of target of interest at tumor site 
(Tabernero et al., 2013, Davis et al., 2010). These studies showed the potential of 
RNAi-based therapy as a promising strategy in cancer management. However, there 
are still critical steps to be taken in the development of RNAi based therapeutics. These 
include the delivery (accumulation, uptake, and intracellular trafficking) and siRNA 
target selection and validation (Wu et al., 2014). 
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Figure 4. Overcoming obstacles in RNAi delivery  
This figure is used with permission and originally published by Wu, S. Y., Lopez-Berestein, G., Calin G. A., Sood A. 
K., in 2014 in Science Translational Medicine 
 
Wu and her colleagues summarize the overall strategy in five sub-aims (Figure 4). 
Target selection and validation are as critical as nanocarrier characterization. In 
addition, relevant toxicology, pharmacology, and pharmacokinetics should be 
considered and toxic immune mediated reactions should be assessed in the early steps 
of the development. In this study, we also aimed to take the initial steps of the 
development and characterization of a novel RNAi-based therapeutic agent. 
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Metastasis 
 
Metastasis is a multistep process that requires the acquisition of genetic and epigenetic 
alterations within a tumor cell (Valastyan and Weinberg, 2011). Initially, tumor cells 
detach from the extracellular matrix and invade through the surrounding tissue. Next, 
the cells migrate towards a vascular supply and penetrate into the vessels, followed by 
gaining access to the systemic circulation. The last step is the extravasation of these 
tumor cells into organ parenchyma and their proliferation in the distant organs in an 
appropriate microenvironment (Figure 5) (Talmadge and Fidler, 2010). 
 
 
 
Figure 5. Invasion-metastasis cascade  
This figure is used with permission and originally published by Talmadge JE and Fidler IJ in 2010 
 
  
 27 
Hence, the tumor cells can repeat the entire cascade that can lead to additional 
metastases (Langley and Fidler, 2011).  
 
Historically, metastasis was thought to be a random case. However, in 1889, Stephen 
Paget declared that the organ distribution of metastases in breast cancer patients was 
not random and he suggested that some tumor cells (seed) tend to grow in the 
microenvironment of selected organs (soil) (Paget, 1889). Schackert and Fidler also 
demonstrated that some tumor cells metastasize to specific regions within an organ 
(Langley and Fidler, 2011, Schackert and Fidler, 1988). 
 
Ovarian cancer has the propensity to spread to the abdominal cavity and forms nodules 
on the surface of peritoneum including omentum. But the mechanism of spread was not 
known. However in a recent study, Sunila Pradeep and her colleagues demonstrated 
that circulating tumor cells localize and proliferate in the omentum and spread to the 
other peritoneal surfaces. They used a parabiosis model where the skins of two mice 
were surgically fused (Pradeep et al., 2014). The study showed that an increased level 
of ErbB3 in ovarian cancer cells and NRG1 in the omentum is responsible for the 
hematogenous omental metastasis.  
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Anoikis 
 
Anoikis is a form of cell death subsequent to loss of contact with extracellular matrix or 
neighboring cells. However cancer cells develop resistance to anoikis and survive in the 
absence of this contact. Therefore, disrupting the anoikis resistance in tumor cells may 
be an effective strategy to prevent metastasis (Young et al., 2013). 
 
Epithelial cells require adhesion to extracellular matrix through cell surface receptors 
known as integrins. Integrins are heterodimers that consists of α and β subunits. There 
are 18 α and 8 β subunits of integrins. The integrin ligation leads to cell adhesion, 
migration and survival through tranducing the signals whereas unligated integrins 
induce apoptosis and prevent non-tumorigenic cells to survive in an inappropriate 
environment (Desgrosellier and Cheresh, 2010). Integrins serve as a mechanosensor 
through monitoring the extracellular environment and become activated via tensional 
forces and mechanical stress (Nagano et al., 2012). The cytoplasmic β tail is essential 
in transducing the signaling that can be initiated either outside or inside the cell. 
Intracellular proteins that are known to bind this region include talin, kindlins and 
filamins (Harburger and Calderwood, 2009). 
 
Integrins activate multiple oncogenic pathway that also activates cell survival and 
motility (Guo and Giancotti, 2004). Integrin ligation activates Focal Adhesion Kinase 
(FAK) – a nonreceptor tyrosine kinase that can phosphorylate both itself at Y397 and 
other cellular proteins such as Src and p85 subunit of PI3K, mediating cell survival and 
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migration (Figure 6). In addition, integrin signaling can induce BCL2, which is anti-
apoptotic to prevent the cells from undergoing apoptosis (Zhang et al., 1995)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Anoikis and integrins  
This figure is used with permission and originally published by Young, S. A., Graf, R. & Stupack, D. G. in 2013, in 
Neuroblastoma Integrins. 
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Hypothesis and Aims of The Study 
 
The poor survival of ovarian cancer patients is associated with advanced disease at the 
time of diagnosis. However, few effective strategies to target this metastatic process 
currently are known; this highlights the need for a deeper understanding of the 
molecular mechanisms that regulate OC growth and progression. To identify new 
therapeutic targets and strategies, we carried out an integrated analysis of The Cancer 
Genome Atlas (TCGA) HGSOC dataset and gene profiles of ovarian and breast tumors 
to identify genes that are important for cancer metastasis. Among the genes identified, 
zinc finger protein 304 (ZNF304) was found to be highly associated with overall survival 
in HGSOC patients. ZNF304 is a transcription factor that belongs to the C2H2 zinc 
finger family. The member genes of this family represent the largest class of 
transcription factors in humans and, indeed, one of the largest gene families in 
mammals (Tadepally et al., 2008). ZNF304 can be upregulated by activated Kirsten rat 
sarcoma viral oncogene homolog (KRAS) in KRAS-positive colorectal cancer cells and 
binds at the promoters of INK4-ARF and other CpG island methylator phenotype genes 
in colorectal cancer cells and in human embryonic stem cells (Serra et al., 2014). 
However, the role of ZNF304 in metastasis and its downstream effectors are not well 
understood.  
Synthetic siRNAs are an effective gene-silencing tool. However, its disadvantage is its 
rapid degradation by serum nucleases, poor cellular uptake and rapid renal clearance 
following systemic administration. Nanomedicine provides for safe and effective for the 
systemic administration of siRNA. In the nanotechnology component of the project, a 
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novel dual assembly nanoparticle system (DANP) is developed and characterized for 
the in vivo delivery of ZNF304 siRNA. The goal was to improve functional applications 
of DANP to maintain a constant siRNA level by releasing at a predetermined rate over 
an extended period of time with minimum side effects. Here, we aimed to unravel the 
mechanisms by which ZNF304 promotes cancer metastasis and to evaluate its role as a 
potential therapeutic target using siRNA and Dual Assembly Nanoparticles (DANP). 
 
Overall hypothesis of the present study is: 
 
Dual assembly nanoparticles (DANP) loaded with ZNF304 siRNA will lead to prolonged 
silencing of the target gene and antitumor activity in orthotopic models of OC. 
 
We tested this hypothesis with the following specific aims: 
 
Specific Aim 1. To identify a novel target gene and determine its mechanism of action 
in OC 
Specific Aim 2. To develop and characterize siRNA loaded DANP and to demonstrate 
that DANP-siRNA leads to sustained silencing of target genes in an orthotopic model of 
ovarian cancer. 
Specific Aim 3. To demonstrate the antitumor activity of DANP siRNA in orthotopic 
models of ovarian cancer.  
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CHAPTER II: Methods 
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Integrative computational analysis and patient data selection 
Clinical and expression data (Level 3 Illumina HiSeqv2) for 260 patients were 
downloaded from The Cancer Genome Atlas portal and were used to analyze the 
relationship between expression of ZNF304 and overall survival as well as between 
expressions of ZNF304 and ITGB1. The Spearman's rank-order correlation test was 
applied to measure the strength of the association between ZNF304 and ITGB1 levels 
in patient samples in TCGA dataset. 
 
Cell lines and culture. The immortalized non-transformed human ovarian surface 
epithelial cell line HIO-180 and the human epithelial OC cell lines HeyA8, MDAH 2774, 
SKOV3IP1, A2780PAR, and A2780CP20 were maintained as described previously 
(Kamat et al., 2007, Lu et al., 2007b, Lu et al., 2007a, Sood et al., 2001, Thaker et al., 
2004). Taxane resistant HeyA8MDR and SKOV3-TR cells were maintained in Roswell 
Park Memorial Institute 1640 medium supplemented with 10% fetal bovine serum and 
0.1% gentamicin sulfate (Gemini Bio-Products) with or without paclitaxel (300 ng/ml for 
HeyA8-MDR; 150 ng/ml for SKOV3-TR). The A2780CP20 cell line was developed by 
sequential exposure of the A2780 cell line to increasing concentrations of cisplatin. All 
of the cell lines are routinely screened for Mycoplasma species (Mycoalert Mycoplasma 
Detection Kit, Lonza). All in vitro and in vivo experiments were conducted when cells 
were 70% to 80% confluent. 
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Western blot analysis. Western blot analysis was performed as previously reported 
(Landen et al., 2005, Halder et al., 2006). All antibodies used in this study and vendors 
are listed in Appendix in Table 3. 
 
SiRNA constructs and delivery. SiRNAs were purchased from Qiagen or Sigma-Aldrich. 
A non-silencing siRNA that did not share sequence homology with any known human 
mRNA was used as a control for target siRNA. In vitro transient transfection was 
performed as described previously (Landen et al., 2005). The ZNF304 siRNA 
sequences are listed in Appendix in Table 2.  
 
Invasion and migration assays. Cell migration and invasion assays have been described 
previously (Spannuth et al., 2009). For migration assays, cells were treated with either 
control or ZNF304 siRNA for 72 hours. Then, cells were re-suspended in serum-free 
medium (5 × 104 cells/ml), and 1 ml of the cell solution was added to gelatin-coated 
inserts. The inserts were then transferred to wells filled with serum-containing medium. 
Cells were allowed to migrate for 6 hours at 37°C. Migrated cells on the bottom of the 
wells were collected, fixed, stained, and counted by light microscopy. Cells were 
counted in 10 random fields (× 200 final magnification), and the average number of 
migrated cells was calculated; the percentage of migration was determined by setting 
control siRNA-treated samples as 100% migration. 
For invasion assays, cells were treated with control or ZNF304 siRNA for 48 
hours. Then, cells were resuspended in serum-free medium (5 × 104 cells/ml), and 1 ml 
of the cell solution was added to inserts coated with a defined matrix consisting of 
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human laminin, type IV collagen, and gelatin (Kim et al., 2011). Inserts were then 
transferred to wells filled with serum-containing medium. Cells were then allowed to 
invade for 24 hours at 37°C. Migrated cells on the bottom of the wells were collected, 
fixed, stained, and counted by light microscopy. Cells were counted in 10 random fields 
(× 200 final magnification), and the average number of migrated cells was calculated; 
the percentage of migration was determined by setting the control siRNA-treated 
samples as 100% invasion. 
 
RPPA. This study was conducted in The University of Texas MD Anderson Cancer 
Center Institution RPPA Core Facility, and the method was described previously (Tibes 
et al., 2006). In brief, cellular proteins were denatured by 1% sodium dodecyl sulfate 
(with beta-mercaptoethanol) and were diluted in 5 2-fold serial dilutions in dilution buffer 
(lysis buffer containing 1% sodium dodecyl sulfate). Serial diluted lysates were arrayed 
on nitrocellulose-coated slides (Grace Bio-Labs) with an Aushon 2470 arrayer (Aushon 
BioSystems). A total of 5808 array spots were arranged on each slide, including the 
spots corresponding to positive and negative controls prepared from mixed cell lysates 
or dilution buffer, respectively. Each slide was probed with a validated primary antibody 
plus a biotin-conjugated secondary antibody. In the RPPA analysis, the antibodies were 
used if only the Pearson correlation coefficient between RPPA and Western blotting 
was greater than 0.7. Antibodies with a single or dominant band on Western blotting 
were further assessed by direct comparison to RPPA using cell lines with differential 
protein expression or modulated with ligands/inhibitors or siRNA for phospho- or 
structural proteins, respectively. The signal obtained was amplified using a Dako 
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Cytomation-catalyzed system and was visualized by diaminobenzidine colorimetric 
reaction. The slides were scanned, analyzed, and quantified using customized software 
(MicroVigene, VigeneTech Inc.) to generate spot intensity. Each dilution curve was fitted 
with a logistic model (“Supercurve Fitting” developed by the Department of 
Bioinformatics and Computational Biology in MD Anderson Cancer Center, 
“http://bioinformatics.mdanderson.org/OOMPA”). This model fits a single curve using all 
the samples (i.e., dilution series) on a slide, with the signal intensity as the response 
variable and the dilution steps as independent variables. The fitted curve was plotted 
with the signal intensities—both observed and fitted—on the y-axis, and the log2-
concentration of proteins plotted on the x-axis for diagnostic purposes. The protein 
concentrations of each set of slides were then normalized by Tukey’s median polish, 
which was corrected across samples by the linear expression values using the median 
expression levels of all antibody experiments to calculate a loading correction factor for 
each sample (Adapted from UT MD Anderson Cancer Center RPPA Core Facility 
website). 
 
Cell-cycle analysis. Cells were transfected with either control siRNA or ZNF304 siRNA, 
trypsinized and collected 72 hours post transfection. Samples were washed in 
phosphate-buffered saline solution (PBS) and were fixed in 75% ethanol overnight. 
Cells were then centrifuged, washed twice in PBS, and reconstituted in PBS with 
propidium iodide (PI; 50 µg/ml), as previously described (Landen et al., 2010). PI 
fluorescence was assessed by flow cytometry, and the percentage of cells in each cycle 
was analyzed by FlowJo software. 
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Chromatin immunoprecipitation assay. HeyA8 cells were cultured in 10% fetal bovine 
serum to ~75% confluence, and cells were cross-linked with 37% formaldehyde for 20 
minutes and were incubated with glycine (0.125 M) for 5 minutes to stop the cross-
linking, as previously described (Cheema et al., 2003). Cells were lysed, and chromatin 
was sonicated according to the protocol provided by the kit (EZ ChIP, Upstate 
Biotechnology; cat #17-371). Possible binding sites of ZNF304 in the ITGB1 promoter 
were predicted using an online tool (http://compbio.cs.princeton.edu/zf/). Six primer pair 
sets were designed using basic local alignment search tool software (National Center 
for Biotechnology Information). Primers used for amplification of the DNA in quantitative 
PCR are shown in Appendix Table 6. Anti-ZNF304 antibody (Table 3) was used for the 
chromatin immunoprecipitation assays. The Bio-Rad DNA Engine Dyad Thermal Cycler 
was used with the following cycling conditions: 2 minutes at 94°C, followed by 35 cycles 
of 30 seconds at 94°C, 30 seconds at 58°C, and 1 minute at 68°C, followed by 1 minute 
at 68°C. 
 
Plasmid construction and luciferase reporter assay. Fragments containing the predicted 
binding sites (BS1, BS2, and BS3) were amplified from HeyA8 cell genomic DNA by 
PCR using primers containing SacI or HindIII restriction enzyme sites. The PCR 
products were purified, digested, and subsequently cloned into the same restriction site 
of the pGL3 control vector (Promega) downstream of the firefly luciferase reporter gene. 
Sequences were analyzed with a DNA BigDye Terminator sequencing kit, version 3.1 
(Life Technologies) HeyA8 cells were plated in 24-well plates (60,000 cells per well) 24 
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hours prior to transfection with either ZNF304 siRNA or ZNF304-expressing vector 
(Promega). Twenty-four hours after the first transfection, cells were transfected with the 
luciferase reporter vectors containing BS1, BS2, or BS3 together with Renilla luciferase 
construct, which was used as a normalization reference. Transfections were performed 
with Attractene transfection reagent (Qiagen) according to the manufacturer’s 
instructions. Cells were lysed 48 hours after luciferase vector transfection, and activity 
was measured using a dual-luciferase reporter assay system (Promega) in the Veritas 
microplate luminometer (Turner BioSystems). Two independent experiments were 
performed in triplicate.  
 
In vitro anoikis. Cells were transfected with control or ZNF304 siRNA and transferred to 
6-well tissue culture plates that were coated with polyhydroxyethylmethacrylate, and 
cells were cultured in these plates for 72 hours at 37°C in a 5% carbon dioxide 
atmosphere. After incubation, cells were detached with 0.5% trypsin/0.1% 
ethylenediaminetetraacetic acid in PBS. Cells were suspended in Roswell Park 
Memorial Institute 1640 medium and were centrifuged at 500 g for 10 minutes. Pellets 
were washed with PBS and were stained with PI solution (50 µg/ml) containing RNase 
A (25 µg/ml). After incubating the pellets for 30 minutes at 37°C, we analyzed cell 
viability by flow cytometry. 
 
Preparation of DANP. DANPs were prepared via ionic gelation of anionic 
tripolyphosphate and siRNA. Briefly, predetermined tripolyphosphate (0.25% 
weight/volume) and siRNA (1 µg/µl) were added to chitosan solution, and the 
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siRNA/chitosan nanoparticles spontaneously formed under constant stirring at room 
temperature. After incubating the nanoparticles at 4°C for 40 minutes, we collected the 
siRNA/DANP by centrifugation (Thermo Biofuge) at 13,000 rpm for 40 minutes at 4°C. 
Chitosan nanoparticles were coated with polylactic acid polymer under probe 
sonication, and the organic solvent was evaporated. The pellet was washed in sterile 
water 3 times to isolate siRNA/DANP, which was stored at 4°C until used. For the 
biodistribution study, DANPs were labeled with rhodamine 6G (Sigma-Aldrich). 
Rhodamine 6G (0.1% weight/volume) was added to the polymer solution (chloroform) in 
the simple emulsion. The particles were collected and were washed 3 times to eliminate 
the nonencapsulated marker. 
 
Orthotopic in vivo models of OC and tissue processing. Female athymic nude mice 
(NCr-nu) (8-12 weeks old) were purchased from the National Cancer Institute-Frederick 
Cancer Research and Development Center (Frederick, MD) and were maintained as 
previously described (Landen et al., 2005). The MD Anderson Cancer Center 
Institutional Animal Care and Use Committee approved and supervised all animal 
studies. Mice were cared for in accordance with guidelines set forth by the American 
Association for Accreditation of Laboratory Animal Care and the United States Public 
Health Service Policy on Human Care and Use of Laboratory Animals. To generate 
tumors, SKOV3IP1 cells (1 × 106) or HeyA8 cells (2.5 × 105) were injected into the 
peritoneal cavity, as previously described (Lu et al., 2008). For therapy experiments, 10 
mice were assigned randomly to each group. This sample size was sufficient to provide 
80% power for a test at significance level of 0.05. As part of preliminary analysis, we 
validated the normality assumption and proceeded with a non-parametric test as 
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appropriate. Treatments with control or ZNF304 siRNA incorporated in DANP were 
intravenously administered either weekly (150 µg/kg body weight) or biweekly (300 
µg/kg body weight). Paclitaxel (100 µg/mouse for the HeyA8 model and 75 µg/mouse 
for the SKOV3 model) was injected intraperitoneally once weekly. Mice were euthanized 
6 weeks after first administration in SKOV3 model and 4 weeks after first administration 
in HeyA8 model. After euthanasia, we recorded mouse and tumor weight, number of 
nodules, and distribution of tumors. Individuals who performed the necropsies were 
blinded to the treatment group assignments. Tissue specimens were fixed with either 
formalin or optimal cutting temperature medium (Miles) or were snap-frozen in liquid 
nitrogen.  
For the biodistribution study of DANP, mice were injected intraperitoneally with 
HeyA8 cells (2.5 × 105) for tumor inoculation. When tumors were palpable, rhodamine 
6G–labeled particles that contained control siRNA (150 µg/kg) were administered 
intravenously. After 24 hours, mice were euthanized; tumors and the major organs 
(brain, heart, kidney, spleen, liver, and lungs) were removed and fixed in optimal cutting 
temperature medium and sectioned. The organ and tumor distribution of particles was 
assessed by fluorescence microscopy. 
For the toxicity study of DANP-siRNA, C57 mice were treated: DANP alone 
(n=6), DANP-Control siRNA (n=6), DANP-ZNF304 siRNA (n=6). Two mice were kept 
without any treatment. 72 hours after the single iv administration mice were 
anesthetized and blood samples were taken through cardiac puncture. Samples (n=3 
mice/group) were analyzed to determine Blood Urea Nitrogen (BUN), Creatinine, 
Alanine Transaminase (ALT), alkaline phosphatase levels and cytokine levels (n=6 
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mice/ group) in blood. Furthermore, 4 organs (brain, spleen, kidney and liver) were 
removed from each mouse. Our pathologist analyzed the hematoxylin and eosin (H&E) 
stained slide of sectioned paraffin tissue specimens in order to determine whether the 
organs exhibit any treatment-related clinical signs of toxicity. 
 
In vivo anoikis. Viability of tumor cells from ascites fluid was determined by dual staining 
with PI and epithelial cell adhesion molecule tagged with fluorescein isothiocyanate. 
MDAH 2774 cells (2 × 106) were injected intraperitoneally into nude mice, and 
treatments started when mice developed detectable ascites. Mice were divided into 2 
groups, (n=3/group) receiving a single administration of either DANP-control siRNA or 
DANP-ZNF304 siRNA (300 µg/kg). After 7 days, ascites fluid was drawn from the 
peritoneal cavity and rapidly centrifuged at 500 g for 10 minutes. Pellets were washed 
with a red blood cell lysis buffer and reconstituted in PBS. Suspended cells were then 
incubated with excited state absorption-fluorescein isothiocyanate (1:30 dilution) for 30 
minutes at room temperature. After incubation, cells were washed and stained with a PI 
solution (50 µg/ml). Cells were then incubated for 30 minutes at 37°C and analyzed on a 
Gallios flow cytometer (Beckman Coulter). 
 
Immunohistochemical analysis. Analyses of tumors cell proliferation and microvessel 
density were conducted by following procedures described previously (Landen et al., 
2006, Langley et al., 2003, Lu et al., 2010). Two investigators quantified the number of 
positive cells in a blinded fashion. The antibodies used and the vendors are listed in 
Appendix Table 3. 
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Statistical analysis. Unless specified otherwise, all data are presented as the mean 
values ± the standard error of the mean from at least 3 independent experiments. Two-
sided t tests were used to test the relationships between the means of data sets, and P 
values indicate the probability of the means compared, being equal with *P < 0.05, **P < 
0.01 and ***P < 0.001. Student’s t tests and analysis of variance were calculated with 
GraphPad software. Statistical analyses were performed in R (version 3.0.1) 
(http:///www.r-project.org/), and P values less than 0.05 were considered statistically 
significant. For the analysis of RPPA results, we used the Benjamini-Hochberg multiple 
testing correction (Benjamini and Hochberg, 1995) to estimate the false discovery rate. 
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CHAPTER III: Results 
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Discovery of ZNF304 and its role in human HGSOC  
 
We first carried out an integrative computational analysis to identify genes that are 
important for cancer metastasis and that are upregulated in ovarian cancer (OC). Since 
N-cadherin has been reported to play a critical role in invasion and anoikis resistance of 
cancer cells (Suyama et al., 2002, Abdul Azis, 2013), we first identified gene signatures 
in tumors with high N-cadherin expression in The Cancer Genome Atlas (TCGA) 
HGSOC dataset. Of 16,869 genes that were upregulated in OC, 493 genes had a 
positive correlation with tumoral N-cadherin expression (Figure 7A). Of these 493 
genes, ciliary neurotrophic factor receptor (CNTFR); melanoma antigen family D, 1 
(MAGED1); nuclear receptor subfamily 2, group F, member 2 (NR2F2), and ZNF304 
were upregulated in invasive ovarian and breast tumor epithelium compared with 
normal ovarian (Bowen et al., 2009) and breast epithelium (Casey et al., 2009), 
respectively.  
We then assessed the effect of tumoral expression on patient survival for these 4 genes 
using TCGA HGSOC dataset. For each gene, we randomly split the entire OC patient 
population into training (2/3 of cases) and validation cohorts (1/3 of cases). In both 
cohorts, patients were divided into sextiles according to mRNA expression, and the first 
and last sextiles were contrasted. Importantly, the relationships between overall survival 
and known prognostic factors such as age or residual disease were examined in both 
the training and the validation cohorts using a Cox proportional hazards model. Only 
ZNF304 was a significant factor in this analysis (Figure 7B and 7C). In contrast, 
CNTFR, MAGED1, and NR2F2 expression levels were not correlated with patient 
survival (Figure 8). Patients with high tumoral ZNF304 expression had significantly 
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lower median overall survival than patients with low tumoral ZNF304 expression (Figure 
7B [training set, 22.2 versus 48.7 months, P = 0.031]; and Figure 7C [validation set, 
40.4 versus 26.9 months, P = 0.039]). Therefore, ZNF304 was selected for additional 
studies.   
 
 
 
 
 
 
 
Figure 7. Increased ZNF304 expression is associated with poor survival in 
HGSOC patients  
(A) Graphical representation of computational analysis using TCGA dataset 
(B) Kaplan- Meier curves for ovarian carcinoma patients based on ZNF304 expression 
in Training set and (C) Validation set. Kaplan- Meier curves indicate that high ZNF304 
expression is a predictor of poor overall survival in OC patients. (n =88, P= 0.03) 
 
A
B C
D E
Figure 1. Significance of ZNF304 expression in human ovarian carcinoma. 
(A) Graphical representation of computatitonal analysis using TCGA dataset
(B) Kaplan- Meier curves for ovarian carcinoma patients based on ZNF304 expression in Training set and (C) Validation set.
Kaplan- Meier curves indicate that high ZNF304 expression is a predictor of poor overall survival in OC patients. (n =88, P= 0.03)
(D) Western Blot analysis of ZNF304 protein expression and (E) RT-PCR analysis of ZNF304 mRNA levels in 7 ovarian cell lines
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(D) Western Blot analysis of ZNF304 protein expression and (E) RT-PCR analysis of ZNF304 mRNA levels in 7 ovarian cell lines
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Figure 8. CNTFR, MAGED1, and NR2F2 expression levels are not correlated with 
patient survival in HGSOC patients  
 
(A) CNTFR expression in Training set (left), and (B) Validation set (right); (C) MAGED1 
expression in Training set (left), and (D) Validation set (right); (E) NR2F2 expression in 
Training set(left), and (F) Validation set (right) 
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Next, we examined protein expression levels of ZNF304 (75 kDa) by Western blot 
analysis in 6 OC tumor cell lines and in HIO180 non-transformed ovarian epithelial cells 
(Figure 9A). ZNF304 protein was highly expressed in all OC cells tested, but a lower 
expression was observed in the HIO180 cells. ZNF304 mRNA basal levels were high in 
4 of the 6 OC cell lines  
(Figure 9B). 
 
 
 
Figure 9. ZNF304 is expressed in ovarian cell lines 
(A) Western Blot analysis of ZNF304 protein expression and (B) RT-PCR analysis of 
ZNF304 mRNA levels in 7 ovarian cell lines 
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(A) Graphical representation of computational analysis using TCGA dataset
(B) Kaplan- Meier curves for ovarian carcinoma patients based on ZNF304 expression in Training set and (C) Validation set.
Kaplan- Meier curves indicate that high ZNF304 expression is a predictor of poor overall survival in OC patients. (n =88, P= 0.03)
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Downregulation of ZNF304 inhibits invasion, migration, and proliferation of OC cells 
 
Given the potential role of ZNF304 in cancer metastasis, we next investigated whether 
silencing this target would affect invasion and migration. We first tested the knockdown 
efficiency of 3 siRNA sequences of ZNF304 in HeyA8 cells (Figure 10). Two of the 3 
siRNA sequences tested (ZNF304 siRNA-1 and ZNF304 siRNA-3) showed more than 
65% inhibition of ZNF304 in HeyA8 cells. Therefore, these 2 siRNA sequences were 
selected for further studies.  
 
 
 
 
 
 
 
 
Figure 10.  ZNF304 siRNA decreases the ZNF304 levels in HeyA8 cells 
 
Western Blot analysis of ZNF304 protein expression 72 hours after Control siRNA or 
ZNF304 siRNA transfection in HeyA8 cells. 
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Next, we performed invasion and migration assays in HeyA8 and SKOV3IP1 cell lines 
with the selected siRNA sequences, resulting in 40% inhibition of invasion and 45% 
inhibition of migration in HeyA8 cells (Figure 11, A and B, respectively) and 27% 
inhibition of migration in SKOV3IP1 cells (Figure 11C).  
 
 
 
 
 
 
 
 
 
 
Figure 11. Silencing ZNF304 inhibits invasion and migration 
 
(A) Invasion %, B) migration % of HeyA8 cells, and (C) migration % of SKOV3IP1 cells. 
Migration and invasion percentages in ZNF304 siRNA treated samples were calculated 
after normalization with control siRNA treated samples. Data presented as mean ± 
SEM. 
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To determine the potential signaling pathways in which ZNF304 is involved, we 
performed a reverse phase protein array (RPPA) analysis of control siRNA-treated and 
ZNF304 siRNA-treated HeyA8 cells. Samples were probed with 214 proteins, including 
total and phospho-proteins. Silencing ZNF304 led to reduced expression of caveolin-1, 
fibronectin, MYH9 (myosin II), and the effectors of the Ras signaling pathway (BRAF, 
RAF1) (Figure 12). Focal adhesion and integrin signaling pathways were significantly 
deregulated in ZNF304-silenced HeyA8 cells. This last finding guided us to further 
analyze the link between ZNF304 and integrin signaling. In addition, ZNF304 mRNA 
expression was highly correlated with β1 integrin expression in HGSOC patient samples 
(r = 0.20, P = 0.0015; Figure 13).  
To further understand the role of ZNF304, we validated the RPPA data and determined 
the levels of focal adhesion complex members after ZNF304 siRNA transfection in 
HeyA8 cells. Silencing ZNF304 decreased phosphorylation of Src and FAK, which are 
adaptor proteins of focal adhesion and major markers of cell migration (Figure 14, A and 
B, respectively). To further analyze pathways related to migration and invasion, we 
investigated the effects of ZNF304 silencing on paxillin and β1 integrin (Figure 14C). 
ZNF304 silencing inhibited both paxillin phosphorylation at tyrosine sites 31 and 118 
and β1 integrin expression in the cell lines tested.  
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Database PATHWAY Count GENES P Value FDR 
KEGG Focal adhesion 7 
CAV1, BRAF, PAK4, MET, 
RAF1, ITGA2, MAPK8, 
FN1 
9.72E-
04 1.0069 
KEGG Insulin signaling 7 
EIF4EBP1, BRAF, TSC2, 
RAF1, MAPK8, RPS6KB1, 
RPS6 
8.41E-
05 0.0875 
PANTHER PDGF signaling 7 
BRAF, STAT5A, RAB11B, 
RAF1, RAB11A, MAPK8, 
RPS6KB1 
0.0026 2.3630 
PANTHER Integrin signaling 6 
CAV1, BRAF, RAF1, 
ITGA2, MAPK8, FN1 0.0275 22.5233 
KEGG Actin cytoskeleton 6 
BRAF, PAK4, RAF1, 
ITGA2, MYH9, FN1 0.0069 6.9846 
PANTHER Interleukin signaling 6 
CDKN1B, BRAF, FOXM1, 
STAT5A, RAF1, FOXO3 0.0238 19.8068 
REACTOME 
 
Insulin 
receptor 
signaling 
6 EIF4EBP1, TSC2, EEF2K, RAF1, RPS6KB1, RPS6 
4.80E-
07 
3.76E-
04 
KEGG p53 signaling 6 
CCNB1, BID, CCNE1, 
TSC2, CASP8, TP53, 
CHEK1 
1.42E-
05 0.0148 
KEGG Cell cycle 6 
CCNB1, CCNE1, CDKN1B, 
SMAD4, TP53, CHEK1, 
RB1 
4.35E-
04 0.4514 
 
Figure 12. RPPA analysis revealed the link between ZNF304 and integrin signaling 
 
Integrated function and pathway analysis were performed using DAVID bioinformatics 
resources (http://david.abcc.ncifcrf.gov/), and significant features were clustered 
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Figure 13. ZNF304 and β1 integrin mRNA levels highly correlates in HGSOC 
patients 
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Figure 14. Silencing ZNF304 leads to reduction in focal adhesion complex 
members 
 
(A) p-src (Y416) and total src levels, (B) Western Blot analysis of FAK phosphorylation 
(C) β1 integrin levels and paxillin phosphorylation levels at tyrosine 31 and tyrosine 118 
sites upon 72 hours ZNF304 siRNA treatment. 
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In the RPPA results, forkhead box M1 (FOXM1) and cyclin B1 levels were also 
decreased in ZNF304-silenced samples, suggesting that ZNF304 might play a role in 
the cell cycle. To determine the effects of ZNF304 silencing on proliferation, we 
performed cell-cycle analysis in HeyA8, SKOV3IP1, A2780PAR, and A2780CP20 cell 
lines after 72 hours of ZNF304 siRNA transfection (Figure 15, A–D, respectively). All 
cell lines treated with ZNF304 siRNA showed significant arrest in the G2 phase, 
confirming the decreases in cyclin B1 and FOXM1 levels found in the RPPA analysis.  
 
 
 
 
 
 
 
 
 
Figure 15. Silencing ZNF304 reduces proliferation through cell cycle arrest 
(A) Cell cycle analysis after 72 hours transfection with Control siRNA or ZNF304 siRNA 
in HeyA8 (B). SKOV3IP1 (C), A2780PAR (D), and A2780CP20 cells (n=3, *P < 0.05, 
**P < 0.01, ***P < 0.001).  
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ZNF304 transcriptionally regulates β1 integrin 
 
The ZNF304 gene is located at chromosome 19q13.43 (www.genome.ucsc.edu). The 
ZNF304 protein consists of a Kruppel-associated box domain and 16 zinc finger 
proteins (UniProt) (Figure 16). To explore the mechanism by which ZNF304 silencing 
downregulates migration, we determined protein and mRNA levels of β1 integrin upon 
ZNF304 siRNA treatment in HeyA8 and SKOV3IP1 cells. Silencing ZNF304 reduced β1 
integrin mRNA levels in these cells (Figure 17). We determined the basal protein levels 
of β1 integrin and observed that it was expressed in the cell lines tested (Figure 18).  
 
 
 
 
 
 
 
 
 
 
 
Figure 16. ZNF304 gene is located at chromosome 19q13.43 and ZNF304 protein 
consists of 16 zinc fingers. 
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Figure 17. Silencing ZNF304 decreases β1 integrin mRNA levels 
Quantification of mRNA levels by Real Time RT-PCR in Control siRNA and ZNF304 
siRNA transfected HeyA8 cells (n=2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. β1 integrin is expressed in all cell lines tested 
Western Blot analysis of basal protein expression of ZNF304 and Integrin β-1  
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We next investigated whether ZNF304 transcriptionally regulates β1 integrin. ZNF304-
DNA binding sites were predicted on the basis of support vector machines (Persikov et 
al., 2009). We identified ten possible ZNF304 binding sites in the β1 integrin promoter 
by using support vector machine scores that ranged from 24.25 to 18.9 (Figure 19A). 
The transcription start site was predicted by the ensemble and was compared with the 
β1 integrin transcript sequence and the binding locations in the β1 integrin promoter 
region (Figure 19B). Six primer sets containing the segments for the 10 binding sites 
were designed (Figure 19C). DNA segments were amplified, cloned, sequenced, and 
confirmed with a standard nucleotide-nucleotide basic local alignment search tool 
(National Center for Biotechnology Information). To determine whether ZNF304 binds to 
the β1 integrin promoter, we performed chromatin immunoprecipitation assays (ChIP) in 
HeyA8 cells with ZNF304 antibody. Subsequent polymerase chain reaction (PCR) 
results confirmed the interaction of β1 integrin promoter and 5 of the 6 predicted 
ZNF304 binding sites (BS1, BS2, BS3, BS5, and BS6) (Figure 19D). A densitometric 
analysis of input and immunoprecipitation results for each binding site revealed that 
BS1, BS2, and BS3 had an affinity of > 50% (Figure 19E). Owing to their affinity, BS1, 
BS2, and BS3 were selected for further studies. 
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Figure 19. ZNF304 binds to β1 integrin promoter 
 
(A) Predicted binding sites of ZNF304 in ITGB1 promoter based on SVM scores using 
an online tool, which is available at http://compbio.cs.princeton.edu/zf/ 
(B) ITGB1 promoter with 10 predicted binding sites, 
(C) Six primer sets that were designed for ten predicted sites 
(D) ChIP analyses with ZNF304 antibody from HeyA8 cells. Relevant sequences were 
quantified by PCR with pre-designed six sets of primers subsequent to ChIP assay, (E) 
densitometric analysis of ChIP analysis. Sequence and antibody specificity controls are 
included. Data are presented as percentage of input. 
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To identify the role of ZNF304 in the regulation of β1 integrin gene transcription, we 
developed 3 constructs that each contained one of the binding sites and inserted them 
into pGL3-basic vector. HeyA8 cells were transfected with the constructs, and the 
activity of each binding site was determined by a dual-luciferase reporter assay in cells 
with basal ZNF304 expression and in cells in which ZNF304 had been knocked down by 
siRNA. As shown in Figure 20A, overall luciferase activity increased in cells transfected 
with the binding site constructs compared with cells transfected with empty vector. Cells 
transfected with BS1-vector had 2 times more luciferase expression than empty vector 
cells, whereas BS2-vector–transfected cells had 6 times more luciferase expression 
than did the empty vector cells. Cells transfected with BS3-vector showed the highest 
luciferase activity (approximately 70 times more expression than empty vector cells). 
ZNF304 silencing led to a decrease in luciferase activity in all 3 binding sites. The most 
significant was BS2-transfected cells, which had a 40.3% inhibition of luciferase activity 
(P = 0.02). We found a 13.8% decrease in luciferase activity for cells transfected with 
BS1-vector and a 7.8% decrease for cells transfected with BS3-vector, compared with 
control cells (P = 0.0173 and P = 0.2630, respectively). Co-transfection of ZNF304-
expressing vector significantly induced the luciferase activity of BS1-, BS2-, and BS3-
vector–transfected cells (Figure 20B). These results indicate that ZNF304 is a positive 
regulator of the active β1 integrin promoter and that ZNF304 increases its transcription 
by binding to BS2.  
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Figure 20. ZNF304 regulates β1 integrin 
 
(A) Luciferase activity upon control siRNA (black) or ZNF304 siRNA (grey) treatment in 
HeyA8 cells. Fold of induction was calculated after normalization with empty vector. 
Data presented as mean ± SEM. 
(B) Luciferase activity upon ZNF304-expressing vector transfection in BS-1, BS2, and 
BS-3 vector transfected HeyA8 cells. Data presented as mean ± SEM. 
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ZNF304 protects tumor cells from anoikis  
 
β1 integrin confers a survival advantage to tumor cells (Vachon, 2011). As a regulator of 
β1 integrin, ZNF304 can also inhibit anoikis through β1 integrin downregulation. 
Therefore, we examined detached HeyA8 cells in vitro using 
polyhydroxyethylmethacrylate (poly-HEMA)-coated tissue culture plates that promote 
anchorage-independent cell growth (Sood et al., 2010). Cells transfected with either of 
the ZNF304 siRNAs for 72 hours had a significantly higher ([ZNF304 siRNA-1, P 
<0.0001]; [ZNF304 siRNA-3, P <0.0005]) rate of anoikis (75%-80%), than control 
untreated or control siRNA-treated cells (60%) (Figure 21A). Consistent with these 
results, immunoblotting from these samples showed that silencing ZNF304 also 
increased poly ADP ribose polymerase (PARP) cleavage (Figure 21B), which supports 
our observation of increased anoikis in cells transfected with ZNF304 siRNA. 
To determine the link between ZNF304-mediated β1 integrin and anoikis, we also 
performed a rescue experiment. HeyA8 and SKOV3IP1 cells were transfected with 
either control siRNA or ZNF304 siRNA. Next, cells were transiently transfected with 
either empty vector or β1 integrin–expressing vector and transferred to anoikis plates. 
Both HeyA8 and SKOV3IP1 cells that were transfected with β1 integrin–expressing 
vector showed increased survival and decreased anoikis rates  (Figure 21C). 
Furthermore, silencing ZNF304 increased the anoikis sensitivity and death rate of 
HeyA8 cells even in the presence of high β1 integrin expression. 
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Figure 21. ZNF304 mediates inside-out signaling 
 
(A) The anoikis rate of HeyA8 cells in suspension condition at 24, 48, and 72 hours in 
vitro (n=3) 
(B) PARP cleavage in ZNF304 siRNA and control siRNA (72 hours) treated samples in 
suspension condition. 
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Figure 21 (continued). ZNF304 mediates inside-out signaling 
(C) The anoikis rate of HeyA8 and SKOV3IP1 cells in suspension condition after 
ZNF304 silencing and β1 integrin overexpression (n=2) 
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Development and characterization of DANP 
 
Size, charge and morphology 
On the basis of our in vitro findings, we next investigated whether ZNF304 gene 
silencing would be effective in treating orthotopic murine models of OC. For the in vivo 
experiments, we developed and characterized a novel delivery system designed for 
sustained and prolonged gene silencing. Dual assembly nanoparticles (DANP) were 
prepared by using a chitosan core coated with polylactic acid (PLA). These particles 
had a diameter of 150-200 nm and a zeta potential of -10 mV, which corresponded to a 
neutral range (Figure 22, A and B, respectively). Atomic force microscopy images 
demonstrated the spherical morphology and size distribution of the DANP (Figure 23). 
This optimized nanoparticle formulation was used for all subsequent experiments owing 
to their small size, slight negative charge, and high efficiency at incorporating siRNA. 
We incorporated siRNA in the chitosan core by using chitosan/tripolyphosphate at a 3:1 
ratio, which yielded more than 75% loading efficiency, as previously described (Lu et al., 
2010).  
Biodistribution 
We next determined the tissue distribution of the DANP by labeling the particles with 
rhodamine 6G and administering these red fluorescence–labeled particles as a single 
dose intravenously to HeyA8 tumor–bearing mice. Twenty-four hours later, the mice 
were euthanized, and their major organs and the tumors were removed, processed, and 
sectioned. The number of particles in each field was assessed by fluorescence 
microscopy (Figure 24). 
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Figure 22. Size and and zeta potential characteristics of DANP 
 
(A) Size and (B) zeta potential of DANP determined by Zeta Sizer (Dynamic Light 
Scattering). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. DANP exhibits spherical morphology 
 
C) Atomic Force Microscopy images of DANP showing the morphology and size 
distribution of particles 
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Figure 24. DANP accumulates in tumor 
Biodistribution of rhodamine 6G-labeled DANP in vivo. Tumor and the major organs 
were removed 24 hours after a single administration of rhodamine 6G labeled DANP. 
The nanoparticles were monitored using fluorescent microscopy and representative 
images were taken at 10X (left) and 20X magnification (right). Number of nanoparticles 
was counted at 5 fields per slide (center). Data are presented as means ± standard 
error of the mean (SEM). 
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Duration of in vivo gene silencing 
In our first set of experiments, we determined the duration of in vivo DANP-mediated 
ZNF304 silencing in an orthotopic HeyA8 mouse model. ZNF304-siRNA-DANP (300 
µg/Kg body weight) was administered as a single intravenous injection 2 weeks after 
tumor inoculation. Groups of mice were euthanized on day 3, 7, and 14 after injection. 
Tumors were collected and analyzed by immunoblotting to determine ZNF304 protein 
expression levels. We demonstrated that ZNF304 protein silencing started at day 3 and 
continued up to 14 days after a single administration of ZNF304-siRNA-DANP (Figure 
25).  
 
 
 
 
 
 
Figure 25. DANP-ZNF304 siRNA downregulates ZNF304 in vivo up to 14 days after 
a single IV injection 
 
Tumors were removed and analyzed by immunoblotting at 3, 7, and 14 days after a 
single administration of ZNF304 siRNA-DANP. 
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Toxicity 
 
To determine whether DANP particles alone or containing siRNA will cause toxicity, we 
assessed the blood chemistries 72 hours after a single IV administration of DANP with 
or without siRNA incorporation. The groups were: NT (n=1), DANP alone (n=3), DANP-
Control siRNA (n=3), DANP-ZNF304 siRNA (n=3). The levels of Alanine Transaminase 
(ALT), Blood Urea Nitrogen (BUN), Creatinine and Alkaline Phosphatase were and 
hematologic parameters in normal range at 72 hours after a single intravenous 
administration of DANP, DANP-Control siRNA, and ZNF304 siRNA (Figure 26, Table 1 
respectively) (Schnell et al., 2002). Plasma samples were also analyzed in order to 
determine whether the treatment caused an inflammatory response. No significant 
difference was observed in cytokine levels at 72 hours after a single systemic 
administration (Figure 27). 
 
Additionally, we removed the major organs (liver, kidney, spleen and brain) in order to 
assess the potential toxicity 72 hours after a single systemic administration. 
Hematoxylin and eosin stained tissues were analyzed by our pathologist and no sign of 
toxicity was observed in any of the groups during the analyses (Figure 28). No clinical 
findings/ abnormalities were observed during animal studies 
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Table 1. Summary data of hematology parameters after administration of Empty DANP, DANP-Control siRNA, DANP-
ZNF304 siRNA 	  
  NT (n=1) Empty DANP 
(n=4) 
  DANP- ControL 
siRNA  (n=4) 
  DANP- ZNF304 siRNA  
(n=4) 
  
Parameter Units Mean Mean Min Max SD Mean Min Max SD Mean Min Max SD  
White Blood Cell 
Count 
 10.e3/uL 1.0 2.8 2.0 4.0 0.9 4.1 2.0 5.6 1.5 4.3 2.3 5.8 1.5  
Red Blood Cell Count  10.e6/uL 10.7 10.1 9.7 10.4 0.4 10.5 10.0 11.0 0.5 10.1 9.7 10.7 0.5  
Hemoglobin  g/dL 15.4 14.8 14.1 15.5 0.6 15.1 14.3 15.5 0.6 14.5 14.0 15.2 0.5  
Hematocrit  % 52.9 50.4 49.4 52.0 1.3 51.9 49.6 54.4 2.2 49.8 48.7 52.6 49.8  
MCV  fL 49.5 49.7 49.1 51.0 49.7 49.2 48.0 50.1 0.8 49.3 48.4 50.1 0.7  
MCH  pg 14.4 14.6 14.4 14.9 0.2 14.4 14.2 14.6 0.2 14.4 14.1 14.9 0.4  
MCHC  g/dL 29.0 29.3 29.2 29.9 29.3 29.2 28.6 29.6 0.4 29.2 28.7 29.1 0.5  
RDW   % 13.3 13.5 13.0 13.9 0.5 13.0 12.7 13.2 0.2 13.4 13.2 13.6 0.2  
Platelet Count  10.e3/uL 582.0 705.0 425.0 833.0 188.3 889.6 834.0 1094.0 889.6 981.3 990.0 1047.0 60.7  
MPV  fL 6.3 6.7 6.1 7.4 0.5 6.3 6.1 6.6 0.2 6.2 6.1 6.3 0.1  
Segs   % 17.2 12.7 11.6 14.0 1.0 9.2 7.4 12.3 2.0 13.7 9.7 16.5 3.2  
Lymphs  % 71.7 78.6 72.0 83.0 4.9 86.3 83.0 88.7 2.1 82.2 79.0 86.3 3.6  
Monos  % 1.7 4.2 1.6 9.0 3.4 1.9 1.1 3.1 0.8 1.5 1.0 1.9 0.4  
Eos   % 8.3 3.5 3.0 5.0 1.1 1.5 1.6 2.6 0.7 1.4 0.9 1.8 0.5  
Basos  % 0.5 0.8 0.2 2.0 1.1 0.2 0.1 0.3 0.1 0.4 0.1 0.6 0.2  
LUC  % 0.7 0.9   0.0 0.8 0.5 1.0 0.2 1.0 0.6 1.6 0.4  
                
 70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. BUN, Creatinine, ALT and alkaline phosphatase levels remain in normal 
range in blood after DANP-ZNF304 siRNA administration 
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Figure 27. No sign of inflammatory response in plasma after DANP-ZNF304 siRNA 
administration 
 
  
Supplementary Figure 7
Supplementary Figure 7. Effect of DANP, DANP-Control siRNA and DANP-ZNF304 siRNA on cytokine levels in plasma,
 72 hours after a single intravenous administration.
No Treatment
DANP
DANP-Control siRNA
DANP-ZNF304 siRNA
1000
2000
3000
4000
5000
6000
7000
8000
0
G-CSFGM-CS
F TNFȬM-CSF IL-1Ȭ IL-1ß IL-2 IL-6 IL-10 KC MIP-2 LIX
pg
/m
L p
las
m
a
72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. No sign of toxicity in liver, kidney, spleen and brain tissues after 
DANP-ZNF304 siRNA administration 
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Effects of ZNF304 gene silencing on antitumor activity in orthotopic models of OC 
 
On the basis of these findings, we examined the antitumor activity of weekly or biweekly 
ZNF304 silencing in 2 orthotopic OC mouse models, HeyA8 and SKOV3IP1. In the first 
model, mice were injected with HeyA8 cells to induce tumors and 1 week later were 
randomly assigned to 6 treatment groups (10 mice in each group): DANP alone, control 
siRNA-DANP, ZNF304-siRNA-DANP (150 µg/Kg body weight) administered weekly, 
and ZNF304-siRNA-DANP (300 µg/Kg body weight) administered biweekly, or, since 
paclitaxel is commonly used for OC treatment and combines effectively with many 
biologically targeted agents, paclitaxel only or a combination of paclitaxel plus ZNF304 
siRNA-DANP (300 µg/Kg body weight, biweekly administration) (Figure 29). Significant 
reductions in tumor weight were observed in the groups treated with ZNF304 siRNA-
DANP weekly or biweekly. Mice treated with ZNF304 siRNA-DANP had a significantly 
lower tumor burden (62% reduction in tumor weight; P < 0.01) (Figure 29, first panel) 
and had 50% fewer nodules than did mice treated with control siRNA-DANP (P < 0.05) 
(Figure 29, second panel). Moreover, the ZNF304 siRNA-DANP treatment group had 
significantly fewer nodules than did the control group (P=0.0001, weekly administration; 
P=0.0001, biweekly administration; student’s t-test).  
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Figure 29. Silencing ZNF304 leads to increased antitumor activity in HeyA8 
orthotopic murine model of OC  
Data presented as mean ± SEM (n=10 mice/group) 
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Figure 6. Effects of in vivo ZNF304 gene silencing on tumor growth and vasculature
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In the second orthotopic model (SKOV3IP1), the treatment groups were (1) control 
siRNA-DANP, (2) ZNF304 siRNA-DANP, (3) control siRNA-DANP plus paclitaxel, and 
(4) ZNF304 siRNA-DANP plus paclitaxel (n=10/group). siRNA-DANP was administered 
intravenously every 2 weeks in all treatment groups. Tumors removed from mice treated 
with ZNF304 siRNA-DANP alone weighed 60% less than those of mice treated with 
DANP-control siRNA. (Figure 30, first row). Number of nodules was dramatically 
reduced in mice treated with either ZNF304 siRNA-DANP or ZNF304 siRNA-DANP plus 
paclitaxel (Figure 30, below). The greatest reduction was observed in the group treated 
with both DANP-ZNF304 siRNA and paclitaxel. None of the groups in either mouse 
model showed decreased body weight, which indicates that the treatments were not 
toxic (Figure 31). These data indicate that inhibiting ZNF304 results in antitumor activity 
in mouse models of OC and that the DANP delivery system is an efficient tool for in vivo 
gene silencing.  
Given the in vitro effects of ZNF304 silencing, we performed Ki67 and CD31 
staining to examine the biological effects of silencing ZNF304 on tumor cell proliferation 
and angiogenesis, respectively. Mice treated with ZNF304 siRNA-DANP showed 
significant reduction in cell proliferation compared to control group (P<0.0001) (Figure 
32, first panel). Given that ZNF304 transcriptionally regulates β1 integrin, which is 
required for endothelial cell adhesion, migration, and survival (Carlson et al., 2008, Weis 
and Cheresh, 2011), we also examined the effects of ZNF304 siRNA treatment on 
angiogenesis. The ZNF304 siRNA-DANP treatment group had significantly reduced 
microvessel density compared with the control (P=0.0252) (Figure 32, second panel). 
 76 
These data showed that downregulation of ZNF304 was highly associated with 
decreased cell proliferation and decreased microvessel density. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Targeting ZNF304 leads to increased antitumor activity in SKOV3 
orthotopic murine model of OC  
Data presented as mean ± SEM (n=10 mice/group) 
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Figure 31. DANP-siRNA treatment does not affect body weight indicating no 
toxicity  
Data presented as mean ± SEM (n=10 mice/group) 
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Figure 32. Silencing ZNF304 decreases proliferation and angiogenesis in vivo 
Data presented as mean ±SEM (n=5 slides /group) 
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Next, we addressed whether ZNF304 silencing could directly increase the rates of 
anoikis in vivo. For this question, we use the OC MDAH 2774 cell line since it causes 
mice to develop ascites (Sood et al., 2010). MDAH 2774 cells were implanted into the 
peritoneal cavity of nude mice, and ascites production was observed 4-6 weeks post-
inoculation. Next, we analyzed the ascites for viable tumor epithelial cells using 
fluorescein isothiocyanate (FITC)-labeled anti-epithelial cellular adhesion molecule 
antibody followed by flow cytometry analysis (Figure 33). The control group showed 
40% epithelial cell death in ascites, whereas mice treated with intravenous ZNF304 
siRNA-DANP had up to 80% epithelial cell death. These results show that silencing 
ZNF304 significantly decreased the ability of OC cells to survive in ascites (P=0.0001, 
Student’s t-test). 
 
 
 
 
 
 
 
Figure 33. Silencing ZNF304 culminate in enhanced anoikis in vivo 
Data presented as mean ±SEM (n=3 mice/group) 
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Figure 6. Effects of in vivo ZNF304 gene silencing on tumor growth and vasculature
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CHAPTER IV: Discussion 
  
 81 
Summary 
 
Ovarian cancer (OC) is lethal. According to statistical estimations, 21980 women will be 
newly diagnosed in 2014 and 14270 women will die due to OC (Siegel et al., 2014). 
Primary reason of elevated death rate is the late-stage presentation of the disease with 
multiple tumor nodules. Hence, more than 70 % of patients with advanced disease 
develop resistance to chemotherapy and experience disease recurrence, which 
generates the second limitation (Romero and Bast Jr, 2012, Bast and Markman, 2010).   
 
Personalized cancer therapy gives the hope of enabling tailored therapies to ameliorate 
survival rates, overcome resistance and decrease toxicity through administration of the 
right drug combination for individuals (Meric-Bernstam and Mills, 2012). It requires 
detailed molecular characterization of patient tumor and its microenvironment that can 
be achieved by rapid identification of novel targets and generation of databases for 
extensive information about markers that predict prognosis, treatment response and 
resistance.  
 
In this current study, we combined the opportunities that were provided by high-
throughput screening technologies supported with bioinformatics, proteomic technology, 
and nanotechnology. We identified ZNF304, through an extensive computational 
analysis and validated its functional significance in OC using Reverse Phase Protein 
Array (RPPA) with subsequent analysis of the potential pathways and downstream 
effectors. We also developed an RNAi delivery system that carry RNAi safely, 
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accumulate at tumor site and release RNAi in a sustained manner leading to decreased 
administration frequency. One of the key findings from this study is that ZNF304 is a 
novel transcriptional regulator of β1 integrin. Silencing ZNF304 with siRNA that is 
incorporated in our delivery system DANP resulted in antitumor activity in orthotopic 
models of OC.  
 
Overall, we have identified a novel zinc finger protein as a contribution in the biology of 
cancer that could open up new avenues not only for OC, but also in a broad range of 
other types of cancer. We also developed and characterized a novel RNAi delivery 
system that will move forward to translational applications in the near future. 
 
Discovery of ZNF304 
 
Elevated metastatic rate and the resistance to chemotherapy are two major issues that 
require improvement for better outcomes in OC patients. The ability for the prediction of 
clinical response should be advanced in order to identify the right combination of drugs 
for individuals. Given the heterogeneity of OC at molecular level, tumors should be 
screened in details using high-resolution comparative genomic hybridization, single 
nucleotide polymorphism analysis, gene and protein expression arrays, and 
immunohistochemistry of relevant markers for an appropriate individually designed 
therapy selection (Meric-Bernstam and Mills, 2012). Besides overcoming the logistic 
challenges, further understanding of the biology is essential that can be only achieved 
by identifying novel targets that have a critical role in survival and metastasis.  
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Therefore, we embarked on a study of identifying a novel target that is significant in 
survival and metastasis. We mined The Cancer Genome Atlas (TCGA), which was 
generated using extensive information and comprehensive analyses of all somatic 
alterations in the cancer genomes (Chin et al., 2011a, Chin et al., 2011b). We identified 
16,869 upregulated genes in OC, and found out the ones that were positively correlated 
with tumoral N-cadherin expression since N-cadherin is crucial in metastasis (Suyama 
et al., 2002, Cavallaro and Christofori, 2004). We were guided to study ZNF304 since 
out of four target genes; only ZNF304 was associated with overall survival in  OC 
patients. The inhibition of invasion and migration of cells after ZNF304 silencing in vitro, 
strengthen the potential of our target selection and led us to perform a protein analysis 
using RPPA technology. RPPA is a fast and sensitive platform that provided us the 
proteomic analysis to understand the potential role of ZNF304 in vitro after silencing 
ZNF304 (Tibes et al., 2006, Stemke-Hale et al., 2008). The comprehensive analysis of 
the RPPA data unraveled the link between ZNF304 and integrin signaling.  
 
Functional Significance of ZNF304 in OC 
 
Integrins are crucial for normal functions of multicellular organisms and critical at each 
step of cancer: tumorigenesis, progression, and metastasis (Desgrosellier and Cheresh, 
2010). Integrins are regulated and activated by conformational changes, clustering, and 
trafficking (Margadant et al., 2011). These transmembrane proteins are an essential link 
 84 
between the extracellular matrix (ECM) and cytoplasm, and the signaling can be in 2 
directions: outside-in or inside-out through the cytoplasmic β tail (Margadant et al., 
2011).  
 
Outside-in signaling. β1 integrin is a subunit of heterodimeric membrane adhesion 
receptors, and it can form heterodimers with integrin α subunits and interact with 
extracellular matrix proteins. For example, α4β1, α8β1, and αvβ1 are fibronectin-binding 
integrins; α3β1, α6β1, and α7β1 interact with laminin and nectin; and α1β1, α2β1, 
α10β1, and α11β1 bind to collagens (Brakebusch and Fässler, 2005, Giancotti, 2000). 
Integrin promotes cell survival and regulates focal adhesion through β1 tail, leading to 
tumor metastasis in many types of cancer including OC (Caccavari et al., 2010, Guo 
and Giancotti, 2004, Grzesiak et al., 2011, Mitra et al., 2011). Furthermore, Schiller and 
colleagues demonstrated that expression of α5β1 integrins is essential to sense the 
stiffness of fibronectin-based ECM via acting as a mechano-sensor in metastasis 
(Minton, 2013, Schiller et al., 2013). Additionally, several β1 integrin-targeting 
strategies, such as monoclonal antibodies and peptide inhibitors, showed activity in 
clinical trials for cancer therapy (Desgrosellier and Cheresh, 2010, Barkan and 
Chambers, 2011, Jahangiri et al., 2014). However, targeting ZNF304—the regulator of 
β1 integrin expression—may offer greater efficacy than targeting only activation of β1 
integrin. 
 
Inside-out signaling. The first study showing the inside-out regulation of β1 integrin 
unraveled the control by R-Ras of the ligand-binding affinity of β1 integrin and 
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fibronectin (Zhang et al., 1996). Thus, the regulation of integrin activation and affinity 
was known as a transcription-independent function of the Ras-linked mitogen-activated 
protein kinase pathway (Hughes et al., 1997, Kinbara et al., 2003). However, the 
transcriptional regulation of β1 integrin remained unknown. Here, we elucidated that the 
regulation of β1integrin expression through ZNF304 at the transcriptional level.  
RPPA analysis revealed that ZNF304 regulates integrin signaling through inhibiting the 
expression of caveolin-1, fibronectin, myosin II, and the effectors of the Ras signaling 
pathway (BRAF, and RAF1). The reduction in β1 integrin and the phosphorylated levels 
of focal adhesion–associated adaptor proteins indicated that ZNF304 may be a master 
regulator of migration (Huttenlocher and Horwitz, 2011). Previous studies showed that 
fibronectin and β1 integrin ligation, followed by activation of cytoplasmic β subunit, 
promotes the invasive migration of OC cells through the ECM (Caswell et al., 2007). 
Myosin II and FAK mediate the phosphorylation of paxillin, reinforcing the cytoskeletal 
ECM linkage and driving focal adhesion maturation (Pasapera et al., 2010). Additionally, 
β1 integrin-FAK signaling directs the initial proliferation of micrometastatic cancer cells 
disseminated in the lungs, which indicates the role of integrin-FAK signaling in the 
metastatic cascade (Shibue and Weinberg, 2009). Thus, ZNF304 may be a regulator of 
this metastatic process. Correspondingly, we provide evidence that silencing the key 
regulator ZNF304 decreased nodule formation and tumor growth in orthotopic mouse 
models of OC. 
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The functional crosstalk between cell adhesion receptors and receptor tyrosine kinases 
contributes to cancer cell survival (Guo and Giancotti, 2004). The interaction between 
ErbB1 and β1 integrin induces tumor cell detachment, migration and metastatic 
potential. β1 integrin was also shown to regulate epidermal growth factor receptor 
signaling in lung cancer cells (Morello et al., 2011) and to mediate epidermal growth 
factor-induced cell invasion in OC cells (Lau et al., 2012). Morello and colleagues 
demonstrated that silencing β1 integrin 
led to decreased proliferation, impaired migration and invasive behavior. Hence, 
silencing β1 integrin leads to a defective activation of EGFR signaling cascade and 
increases EGFR on the surface of the cell, indicating that β1 integrin is essential for 
EGFR turnover on the cell membrane. Therefore silencing ZNF304—the regulator of β1 
integrin—may also inhibit epidermal growth factor receptor signaling, inhibiting cancer 
cell survival and slowing tumor progression. 
 
 
The interaction between ECM and integrins play a critical role in cell migration by 
providing an essential step for cell motility. Adherent cells require anchorage of the cell 
for survival (Meredith et al., 1993, Frisch and Francis, 1994). All communications within 
the microenvironment are in most cases mutually beneficial. Thus, its combination with 
ECM provide life support for the cells (Liotta and Kohn, 2004). Dr. Steven Frisch 
discovered and named this phenomenon as the term “anoikis,” that means 
“homelessness,” and refers to a form of programmed cell death as a result of 
inadequate cell-ECM interaction or absence of cell-ECM attachment (Meredith et al., 
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1993, Frisch and Francis, 1994, Liotta and Kohn, 2004). However, malignant cells 
develop resistance to anoikis, and survive in absence in these signals, leading to an 
elevated metastatic spread (Simpson et al., 2008, Jenning et al., 2013). A recent study 
showed that activated integrins enhance the metastatic potential of prostate cancer cells 
by decreasing their sensitivity to anoikis during tumor dissemination and by increasing 
their interactions with ECM ligands during extravasation (Lee et al., 2013). This study 
suggested that in prostate cancer cells, β1 integrin is activated through an inside-out 
signaling, which also enhances its affinity for ligand binding. The interaction of β1 
integrin with ECM ligands further activates β1 integrin through outside-in signaling, 
suggesting the bidirectional interactions can follow each other leading to further 
activation of integrins, subsequently followed by growth signals. Our in vitro and in vivo 
anoikis results showed that silencing ZNF304 enhances the anoikis rate through 
inhibiting inside-out integrin signaling and accordingly blocking outside-in signaling. 
 
Development and characterization of Dual Assembly Nanoparticles for RNAi 
delivery and sustained down-regulation of targets 
 
In recent years, there has been an explosion in knowledge regarding non-coding RNAs. 
At present, there are several small and long coding RNAs including siRNA, microRNA, 
pyknons, long non-coding RNAs and others (Rigoutsos, 2010, Hansji et al., 2014, Sana 
et al., 2012). We currently know that protein-coding genes represent less than 2% of the 
total genome and non-coding RNAs can regulate DNA, RNA and protein expression 
governing multiple pathways.  
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Given the fact that RNAi based therapies offer a unique opportunity to knockdown 
specific genes and paves the way to personalized medicine in cancer therapy, sufficient 
RNAi delivery is essential. However, a number of pharmacological, physiological and 
biological barriers have to be overcome. This emphasizes the crucial role of 
nanotechnology-based delivery in the development of novel strategies. Early-phase 
RNAi based therapy trials drew the attention to the feasibility of siRNA delivery into 
tumors and the selective knockdown of target of interest at tumor site (Tabernero et al., 
2013, Davis et al., 2010). These studies showed the potential of RNAi-based therapy as 
a promising strategy. However, there are still critical steps to be taken in the 
development of RNAi based therapeutics including the delivery, relevant toxicology, 
pharmacology, and pharmacokinetics that should be assessed in the early steps of the 
development (Wu et al., 2014). In this study, we took the initial steps of the development 
and characterization of DANP-siRNA therapeutic agent. Our group has previously 
developed and characterized chitosan nanoparticles for systemic delivery of siRNA (Lu 
et al., 2010, Han et al., 2010). Although chitosan nanoparticles is an efficient RNA 
interference delivery system, weekly administration is required since the target 
downregulation lasts only for 7 days after a single administration. Our results 
demonstrate that DANP, a combination of 2 biocompatible and biodegradable polymers, 
led to sustained silencing of ZNF304 and antitumor activity with a single administration 
every 2 weeks. Furthermore, according to the level of silencing at 14 days after a single 
DANP-siRNA administration; we expect the silencing of the gene of interest, beyond 14 
days. Thus, DANP is a powerful therapeutic tool that leads to long-term silencing of 
genes and could enhance the use of siRNA and patient compliance. 
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There have been similar attempts in the development of nanoparticles for sustained 
release of the drugs. Ferrari and colleagues designed multistage vector system (MSV) 
that is composed of porous silicon particles loaded with nanoparticles that leads to the 
slow-rate release of siRNA in murine orthotopic models of OC (Tanaka et al., 2010). 
MSV/EphA2 siRNA was administered biweekly for 6 week leading to remarkable tumor 
reduction in vivo (Shen et al., 2013b). They also showed that the carriers highly 
accumulate at tumor site with biodistribution studies and demonstrated that no 
inflammatory response was created after systemic administration (Tanaka et al., 2010).  
 
The toxicity of nanoparticles is crucial in evaluating the potential of carriers at 
development stages of drug delivery systems (Wu et al., 2014). However, there are no 
standards in order to determine the toxicity of nanocarriers. In this study, we studied the 
potential toxicity of DANP in serum 72 hours after a single systemic administration and 
no clinical abnormality was found (Schnell et al., 2002). In addition, following a single 
administration of DANP; no sign of toxicity was observed in the liver, kidney, brain, and 
spleen after a single iv administration, in compliance with no significant difference in 
inflammatory cytokine levels. We similarly observed no significant difference in 
inflammatory cytokines. These data indicate that DANP is a safe and non-toxic. 
 
In vivo validation of target selection and DANP 
 
The treatment of ovarian cancer is still limited to surgery followed by chemotherapy 
especially with platinum and taxane based regimens (Romero and Bast Jr, 2012). 
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Cisplatin is an alkylating agent that leads to inter- or intrachain crosslinks through 
covalently binding to DNA. Paclitaxel increases microtubule stability through non-
covalent interaction and prevents the mitotic spindle formation. Given the fact that 
ZNF304 silencing leads to remarkable reduction in focal adhesion members such as 
FAK and Src, we combined our ZNF304 siRNA treatment with weekly intraperitoneal 
paclitaxel administration in our in vivo antitumor activity studies since focal adhesion 
kinase (FAK) and Src inhibition are shown to be critical for chemotherapy sensitivity, 
previously. FAK inhibition has been shown to sensitize ovarian cancer cells to taxanes 
in vitro and in vivo (Kang et al., 2013). In addition, Huang and his colleagues showed 
that Src inhibitor dasatinib in combination with paclitaxel is sufficient in reduction of 
tumor weight and number of nodules in orthotopic in vivo models of uterine cancer 
(Huang et al., 2014). Additionally, this combination showed its feasibility in Phase I 
studies in breast cancer patients (Gil et al., 2014, Cadoo et al., 2013, Huang et al., 
2014). However; since ZNF304 is a transcription factor and platinum based drugs lead 
to the crosslink of DNA, a combination treatment of ZNF304 siRNA and carboplatin can 
also show enhanced antitumor activity in vivo. Additionally, our data demonstrated that 
ZNF304 silencing caused cell cycle arrest in four ovarian cancer cell lines. Therefore, a 
combination treatment with ZNF304 siRNA and carboplatin may extent the DNA 
damage and increase the chemo sensitivity of cells in vitro. Therefore, the effects of 
ZNF304 silencing with or without carboplatin treatment can be studied in future studies 
in order to unravel whether ZNF304 is linked to platinum resistance. 
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CHAPTER V: Future Directions 
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Translational Application of Dual Assembly Nanoparticles 
This project provided basis for a number of future studies. In particular, we 
demonstrated that DANP is a safe and sufficient delivery system for siRNA. Hence, the 
particles are currently under evaluation by the Nanotechnology Characterization 
Laboratory (NCL). NCL works with the National Institute of Standards and Technology 
(NIST) and the U.S. Food and Drug Administration (FDA), serving as a national 
resource to facilitate the regulatory review for nanotechnology applications. Long-term 
goal of this project is to take DANP-siRNA to clinic and further characterization is 
required for the transition to clinical trials. 
In addition, given the fact that DANP is a polymeric particle, surface chemistries can be 
studied in order to chemically conjugate specific ligands on the surface of DANP for 
active targeting purposes. DANP passively accumulates at tumor site owing to the 
Enhanced Permeability and Retention (EPR) effect; however the presence of specific 
ligands on the nanoparticle will lead to selective uptake of nanoparticles by only tumor 
cells. 
 
Further investigation of the mechanism of ZNF304 
In this study, we showed that ZNF304 regulates β1 integrin, however since it is a novel 
transcription factor, its alternative downstream effectors are currently not known. 
Therefore ChIP sequencing can be performed and effectively analyzed in order to 
identify its additional targets and uncover the biological mechanisms that ZNF304 is 
involved in; not only for OC, but also in other types of cancer. A recent study has shown 
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the link between KRAS and ZNF304 in colorectal cancer, suggesting that KRAS 
promotes silencing through up-regulation of ZNF304, which also regulates 
transcriptional silencing of INK4A-ARF in human embryonic stem cells (Serra et al., 
2014). Further investigation should be performed for the effects of ZNF304 silencing in 
KRAS-driven cancers such as lung and pancreatic cancer.  
 
Determining the role of ZNF304 in chemotherapy resistance 
The worse survival in OC patients is highly associated with chemo-resistance since 
more than 70 % of patients with advanced disease develop resistance to chemotherapy 
and experience disease recurrence, which generates the second limitation (Romero and 
Bast Jr, 2012, Bast and Markman, 2010).  We have examined the effect of combination 
treatment with paclitaxel and ZNF304 silencing in our antitumor activity studies, 
however we have not studied the effect of platinum drugs in combination with ZNF304 
silencing. Proliferation assays can be performed and followed by RPPA array within 
samples that are treated with platinum alone and platinum in combination with ZNF304 
siRNA to find out the relevant downstream targets that ZNF304 might be regulating in 
the resistance mechanism. This project can contribute to the field in terms of identifying 
targets that are significant in chemotherapy resistance. 
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Table 2. siRNA sequences used in zinc finger protein 304 (ZNF304) transfection 
experiments 
 
Name Target Sequence  Source Cat # 
ZNF304 
siRNA-1 
5′-GAUCACACCUUACACAGAA-3′ Sigma-
Aldrich 
SASI_HS01_
00189770 
ZNF304 
siRNA-2 
5′-CUUAUUGAGCACUGGAGAA -3′ Sigma-
Aldrich 
SASI_HS01_
00189771 
ZNF304 
siRNA-3 
5′-GCAACAUAAUGGAGAGAAU-3′ Sigma-
Aldrich 
SASI_HS01_
00189772 
Control 
siRNA 
5′-UUCUCCGAACGUGUCACGUUU-3′ Sigma-
Aldrich 
WD00909801 
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Table 3. Antibodies used in the Western blotting, chromatin immunoprecipitation, 
and immunohistochemical analyses 
 
 
Target Protein Source Cat # Applications  
Actin-beta Sigma-Aldrich A5316 WB 
ZNF304 Sigma-Aldrich SAB2106472 WB, ChIP 
β1 integrin 
Cell Signaling 
Technology 4706S WB 
Akt (pS473) 
Cell Signaling 
Technology 4060S WB 
Akt 
Cell Signaling 
Technology 9272 WB 
FAK (pY397) BD Biosciences 611722 WB 
FAK BD Biosciences 610087 WB 
PARP 
Cell Signaling 
Technology 9542 WB 
Src (p416) 
Cell Signaling 
Technology 6943 WB 
Src 
Cell Signaling 
Technology 2123 WB 
Paxillin (pY118) 
Cell Signaling 
Technology 2541 WB 
Paxillin (pY31) Epitomics 1228-1 WB 
Paxillin  
Cell Signaling 
Technology 2542 WB 
Ki67 Thermo Scientific RB9043-P IHC 
CD31 BD Biosciences 53370 IHC 
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Table 4. Oligonucleotide sequences for quantitative reverse transcription 
polymerase chain reaction 
 
Target  
Gene              Forward Sequence                               Reverse Sequence 
ZNF304
-set 1 
5′-GCACAGAGATTCCTGTACCGT-
3′ 
5′-
TTTCAAGAGTGGGTCACACATC-
3′ 
ZNF304
-set 2 
5′-GTGTGACCCACTCTTGAAAGAC-
3′ 
5′-
CCCTCTGAAGCAATTCTCTCCA
T-3′ 
ZNF304
-set 3 
5′-TGGAGGGGCCTCATTTGTG-3′ 5′-
CTCCCTGCACGTAAAGGATCT-
3′ 
ITGB1-
set 1 
5′-CCTACTTCTGCACGATGTGATG-
3′ 
5′-
CCTTTGCTACGGTTGGTTACAT
T-3′ 
ITGB1-
set 2 
5′-GTAACCAACCGTAGCAAAGGA-
3′ 
5′-
TCCCCTGATCTTAATCGCAAAA
C-3′ 
ITGB1-
set 3 
5′-
CAAGAGAGCTGAAGACTATCCCA-
3′ 
5′-
TGAAGTCCGAAGTAATCCTCCT-
3′ 
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Table 5. Oligonucleotide sequences for quantitative polymerase chain reaction 
analysis of chromatin immunoprecipitation assays 
 
Gene 
Amplicon 
location 
Forward sequence Reverse sequence 
ITGB1 3775-
3725 
GGGTTGAGGAGAGGGAAGGTA TGCCTTTCAGTTGCTGTCCTAA 
ITGB1 3392-
3297 
AAGGCCAGCAGCATTGAAAG AGAACACAGAAGAGCTACAGGAC 
ITGB1 3155-
3108 
TCTGTTTCTTGCCAGTGCCC CCTTCTGAAACCCTTGTGCC 
ITGB1 1989-
1939 
TTTGCCTTGAGAAAGTCACG TCCTGTAATCCCAGCTTCTCA 
ITGB1 1546-
1496 
TGTGTGTGTATATGTGTGTCACCTT TGCGAGAAACCAACTGGTAG 
ITGB1 784-613 TCCCAGGTTCAAGCAGTTCTC GCTCACGCCTGGAATCTCA 
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